[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fcMb0unxI5HURqT-2iykBDq6M2K5iMAxI7Aah0Byez0w":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":87,"rows":94},"Ottawa Hospital Research Institute",[4],532,false,88,49,2823780,42,370,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Breast Cancer",34,{"name":18,"count":19},"Cancer",20,{"name":21,"count":22},"Venous Thromboembolism",19,{"name":24,"count":25},"Osteoarthritis",15,{"name":27,"count":28},"Cardiac Arrest",12,{"name":30,"count":31},"Hypertension",9,{"name":33,"count":34},"Surgery",8,{"name":36,"count":34},"Deep Vein Thrombosis",[38,43,48,53,58,63,68,72,77,82],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT00936819","The Enhanced Angiogenic Cell Therapy - Acute Myocardial Infarction Trial","2020-03-05","Plasma-Lyte A and 25% Autologous Plasma",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT04255147","Cellular Therapy for Extreme Preterm Infants at Risk of Developing Bronchopulmonary Dysplasia","2023-11-06","Allogeneic Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT05766397","Prehospital Inhaled Methoxyflurane Non-Clinical Occupational Exposure Study","2024-07-20","Methoxyflurane",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT04744675","Peripheral Nerve Injections for CRPS","2024-07-30","Triamcinolone Acetonide 40mg\u002FmL",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT04754061","PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL)","2025-01","Psilocybin",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT06827041","Use of Phage Therapy for Treatment of a Periprosthetic Joint Infection","2025-02","Phage",{"nctId":69,"briefTitle":70,"date":71,"intervention":52},"NCT06392087","Prehospital Analgesia in Adults Using Inhaled Methoxyflurane Study","2025-03-01",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT04549207","Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer","2025-04-17","Bone modifying agent",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT04705896","Albumin To Enhance Recovery After Acute Kidney Injury","2025-08-28","20-25% Albumin fluid",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT05754528","Evaluating an Endocrine Therapy Dose-frequency Escalation Strategy and Its Effects on Tolerability and Compliance","2025-11-25","Standard of care administration of Endocrine therapy",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,167,210,237,273,296,321,347,365,391,416,437,455,500,559,625,650,676,700,718,736,754,782,800,826,853,880,912,938,963,985,1010,1032,1050,1078,1102,1120,1138,1182,1202,1223,1276,1294,1324,1359,1393,1421,1458,1486,1511,1529,1555,1573,1597,1622,1647,1665,1691,1717,1745,1771,1789,1814,1832,1850,1876,1894,1912,1936,1962,1980,1998,2022,2047,2073,2091,2114,2132,2156,2180,2198,2216,2234,2252,2285,2319,2356,2390,2408,2432,2458,2484,2502,2530,2548,2573,2591,2618,2636,2660,2684,2710,2736,2754,2780,2798,2822,2847,2865,2888,2906,2932,2962,3005,3038,3063,3088,3110,3133,3151,3176,3200,3224,3249,3273,3296,3321,3346,3368,3393,3411,3435,3458,3483,3506,3531,3556,3579,3601,3624,3647,3672,3690,3708,3734,3756,3780,3802,3828,3846,3868,3891,3912,3935,3953,3978,4004,4022,4044,4062,4118,4148,4188,4222,4254,4275,4293,4311,4334,4356,4382,4407,4433,4456,4479],{"intervention":96,"totalTrials":97,"cells":98},"Apixaban",5,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":104,"PHASE3":117,"PHASE4":119,"NA":165},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":101},[],{"trials":105,"activeCount":101},[106],{"nctId":107,"briefTitle":108,"status":109,"phases":110,"primaryCompletion":111,"completion":112,"start":113,"enrollment":114,"conditions":115,"interventions":116},"NCT02048865","Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients","COMPLETED",[90],"2018-10-10","2018-10-19","2014-03-24",575,[21,18],[96],{"trials":118,"activeCount":101},[],{"trials":120,"activeCount":164,"soonestReadout":148},[121,132,144,154],{"nctId":122,"briefTitle":123,"status":109,"phases":124,"primaryCompletion":125,"completion":126,"start":127,"enrollment":128,"conditions":129,"interventions":130},"NCT02559856","Comparison of Bleeding Risk Between Rivaroxaban and Apixaban: The Pilot Study",[92],"2017-11","2018-02","2016-05",72,[21],[96,131],"Rivaroxaban",{"nctId":133,"briefTitle":134,"status":135,"phases":136,"primaryCompletion":137,"completion":137,"start":138,"enrollment":139,"conditions":140,"interventions":143},"NCT06603870","Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis","RECRUITING",[92],"2029-10","2024-12-19",330,[21,18,141,142],"Upper Extremity Deep Vein Thrombosis","Catheter-Related Infections",[96],{"nctId":145,"briefTitle":146,"status":135,"phases":147,"primaryCompletion":148,"completion":148,"start":149,"enrollment":150,"conditions":151,"interventions":153},"NCT04642430","COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation",[92],"2027-12-31","2021-07-06",3018,[152],"Atrial Fibrillation",[96,131],{"nctId":155,"briefTitle":156,"status":109,"phases":157,"primaryCompletion":158,"completion":159,"start":160,"enrollment":161,"conditions":162,"interventions":163},"NCT03266783","Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism",[92],"2025-04-30","2025-09-08","2017-12-13",2760,[21],[96,131],2,{"trials":166,"activeCount":101},[],{"intervention":52,"totalTrials":168,"cells":169},3,{"EARLY_PHASE1":170,"PHASE1":172,"PHASE2":174,"PHASE3":176,"PHASE4":178,"NA":208},{"trials":171,"activeCount":101},[],{"trials":173,"activeCount":101},[],{"trials":175,"activeCount":101},[],{"trials":177,"activeCount":101},[],{"trials":179,"activeCount":164,"soonestReadout":51},[180,191,200],{"nctId":181,"briefTitle":182,"status":109,"phases":183,"primaryCompletion":184,"completion":184,"start":185,"enrollment":186,"conditions":187,"interventions":190},"NCT04287803","Prehospital Analgesia in Adults Using Inhaled Methoxyflurane : A Feasibility Study",[92],"2021-11-01","2021-04-12",97,[188,189],"Pain, Acute","Trauma",[52],{"nctId":49,"briefTitle":50,"status":192,"phases":193,"primaryCompletion":51,"completion":194,"start":195,"enrollment":196,"conditions":197,"interventions":199},"ENROLLING_BY_INVITATION",[92],"2024-09-30","2023-09-01",30,[198],"Occupational Exposure",[52],{"nctId":69,"briefTitle":70,"status":201,"phases":202,"primaryCompletion":71,"completion":203,"start":204,"enrollment":205,"conditions":206,"interventions":207},"NOT_YET_RECRUITING",[92],"2025-12-31","2024-08-01",1800,[188],[52],{"trials":209,"activeCount":101},[],{"intervention":131,"totalTrials":168,"cells":211},{"EARLY_PHASE1":212,"PHASE1":214,"PHASE2":216,"PHASE3":218,"PHASE4":220,"NA":235},{"trials":213,"activeCount":101},[],{"trials":215,"activeCount":101},[],{"trials":217,"activeCount":101},[],{"trials":219,"activeCount":101},[],{"trials":221,"activeCount":234,"soonestReadout":148},[222,226,230],{"nctId":122,"briefTitle":123,"status":109,"phases":223,"primaryCompletion":125,"completion":126,"start":127,"enrollment":128,"conditions":224,"interventions":225},[92],[21],[96,131],{"nctId":145,"briefTitle":146,"status":135,"phases":227,"primaryCompletion":148,"completion":148,"start":149,"enrollment":150,"conditions":228,"interventions":229},[92],[152],[96,131],{"nctId":155,"briefTitle":156,"status":109,"phases":231,"primaryCompletion":158,"completion":159,"start":160,"enrollment":161,"conditions":232,"interventions":233},[92],[21],[96,131],1,{"trials":236,"activeCount":101},[],{"intervention":238,"totalTrials":164,"cells":239},"Cephalexin",{"EARLY_PHASE1":240,"PHASE1":242,"PHASE2":244,"PHASE3":246,"PHASE4":248,"NA":271},{"trials":241,"activeCount":101},[],{"trials":243,"activeCount":101},[],{"trials":245,"activeCount":101},[],{"trials":247,"activeCount":101},[],{"trials":249,"activeCount":234,"soonestReadout":265},[250,261],{"nctId":251,"briefTitle":252,"status":109,"phases":253,"primaryCompletion":254,"completion":254,"start":255,"enrollment":256,"conditions":257,"interventions":259},"NCT04471246","High-dose vs. Standard-dose Cephalexin for Cellulitis",[92],"2022-02-23","2021-08-16",69,[258],"Cellulitis",[238,260],"Cephalexin + placebo",{"nctId":262,"briefTitle":263,"status":192,"phases":264,"primaryCompletion":265,"completion":266,"start":267,"enrollment":268,"conditions":269,"interventions":270},"NCT05852262","High-dose Cephalexin for Cellulitis (HI-DOCC)",[92],"2025-12","2026-08-01","2023-08-30",446,[258],[238,238],{"trials":272,"activeCount":101},[],{"intervention":76,"totalTrials":234,"cells":274},{"EARLY_PHASE1":275,"PHASE1":277,"PHASE2":279,"PHASE3":281,"PHASE4":283,"NA":294},{"trials":276,"activeCount":101},[],{"trials":278,"activeCount":101},[],{"trials":280,"activeCount":101},[],{"trials":282,"activeCount":101},[],{"trials":284,"activeCount":234,"soonestReadout":75},[285],{"nctId":73,"briefTitle":74,"status":286,"phases":287,"primaryCompletion":75,"completion":288,"start":289,"enrollment":290,"conditions":291,"interventions":293},"ACTIVE_NOT_RECRUITING",[92],"2026-06","2020-10-09",240,[15,292],"Castration-resistant Prostate Cancer",[76],{"trials":295,"activeCount":101},[],{"intervention":297,"totalTrials":234,"cells":298},"Trastuzumab",{"EARLY_PHASE1":299,"PHASE1":301,"PHASE2":303,"PHASE3":305,"PHASE4":307,"NA":319},{"trials":300,"activeCount":101},[],{"trials":302,"activeCount":101},[],{"trials":304,"activeCount":101},[],{"trials":306,"activeCount":101},[],{"trials":308,"activeCount":234,"soonestReadout":313},[309],{"nctId":310,"briefTitle":311,"status":286,"phases":312,"primaryCompletion":313,"completion":314,"start":315,"enrollment":316,"conditions":317,"interventions":318},"NCT04928261","Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy",[92],"2025-12-15","2028-12","2021-12-13",52,[15],[297],{"trials":320,"activeCount":101},[],{"intervention":322,"totalTrials":234,"cells":323},"Granulocyte Colony-Stimulating Factor",{"EARLY_PHASE1":324,"PHASE1":326,"PHASE2":328,"PHASE3":330,"PHASE4":332,"NA":345},{"trials":325,"activeCount":101},[],{"trials":327,"activeCount":101},[],{"trials":329,"activeCount":101},[],{"trials":331,"activeCount":101},[],{"trials":333,"activeCount":234,"soonestReadout":338},[334],{"nctId":335,"briefTitle":336,"status":135,"phases":337,"primaryCompletion":338,"completion":338,"start":339,"enrollment":340,"conditions":341,"interventions":343},"NCT05753618","Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy",[92],"2026-10","2023-04-17",242,[342],"Early-stage Breast Cancer",[322,344],"Omission of Granulocyte Colony-Stimulating Factor",{"trials":346,"activeCount":101},[],{"intervention":344,"totalTrials":234,"cells":348},{"EARLY_PHASE1":349,"PHASE1":351,"PHASE2":353,"PHASE3":355,"PHASE4":357,"NA":363},{"trials":350,"activeCount":101},[],{"trials":352,"activeCount":101},[],{"trials":354,"activeCount":101},[],{"trials":356,"activeCount":101},[],{"trials":358,"activeCount":234,"soonestReadout":338},[359],{"nctId":335,"briefTitle":336,"status":135,"phases":360,"primaryCompletion":338,"completion":338,"start":339,"enrollment":340,"conditions":361,"interventions":362},[92],[342],[322,344],{"trials":364,"activeCount":101},[],{"intervention":366,"totalTrials":234,"cells":367},"Neomycin and Flagyl",{"EARLY_PHASE1":368,"PHASE1":370,"PHASE2":372,"PHASE3":374,"PHASE4":376,"NA":389},{"trials":369,"activeCount":101},[],{"trials":371,"activeCount":101},[],{"trials":373,"activeCount":101},[],{"trials":375,"activeCount":101},[],{"trials":377,"activeCount":234,"soonestReadout":382},[378],{"nctId":379,"briefTitle":380,"status":286,"phases":381,"primaryCompletion":382,"completion":383,"start":384,"enrollment":385,"conditions":386,"interventions":388},"NCT03663504","Comparing No Mechanical Bowel Preparation With Oral Antibiotics Alone in Patients Undergoing Elective Colon Surgery",[92],"2026-05","2026-07","2018-10-23",630,[387],"Elective Colon Surgery",[366],{"trials":390,"activeCount":101},[],{"intervention":81,"totalTrials":234,"cells":392},{"EARLY_PHASE1":393,"PHASE1":395,"PHASE2":397,"PHASE3":399,"PHASE4":401,"NA":414},{"trials":394,"activeCount":101},[],{"trials":396,"activeCount":101},[],{"trials":398,"activeCount":101},[],{"trials":400,"activeCount":101},[],{"trials":402,"activeCount":234,"soonestReadout":80},[403],{"nctId":78,"briefTitle":79,"status":135,"phases":404,"primaryCompletion":80,"completion":405,"start":406,"enrollment":407,"conditions":408,"interventions":413},[92],"2025-10-23","2023-11-02",856,[409,410,411,412],"Acute Kidney Injury","Renal Replacement Therapy","Hypotension","Critical Illness",[81],{"trials":415,"activeCount":101},[],{"intervention":86,"totalTrials":234,"cells":417},{"EARLY_PHASE1":418,"PHASE1":420,"PHASE2":422,"PHASE3":424,"PHASE4":426,"NA":435},{"trials":419,"activeCount":101},[],{"trials":421,"activeCount":101},[],{"trials":423,"activeCount":101},[],{"trials":425,"activeCount":101},[],{"trials":427,"activeCount":234,"soonestReadout":85},[428],{"nctId":83,"briefTitle":84,"status":286,"phases":429,"primaryCompletion":85,"completion":430,"start":431,"enrollment":290,"conditions":432,"interventions":433},[92],"2030-02","2023-07-28",[15],[86,434],"Dose-frequency escalation administration of Endocrine therapy",{"trials":436,"activeCount":101},[],{"intervention":434,"totalTrials":234,"cells":438},{"EARLY_PHASE1":439,"PHASE1":441,"PHASE2":443,"PHASE3":445,"PHASE4":447,"NA":453},{"trials":440,"activeCount":101},[],{"trials":442,"activeCount":101},[],{"trials":444,"activeCount":101},[],{"trials":446,"activeCount":101},[],{"trials":448,"activeCount":234,"soonestReadout":85},[449],{"nctId":83,"briefTitle":84,"status":286,"phases":450,"primaryCompletion":85,"completion":430,"start":431,"enrollment":290,"conditions":451,"interventions":452},[92],[15],[86,434],{"trials":454,"activeCount":101},[],{"intervention":456,"totalTrials":168,"cells":457},"Rivaroxaban 10 MG",{"EARLY_PHASE1":458,"PHASE1":460,"PHASE2":462,"PHASE3":464,"PHASE4":496,"NA":498},{"trials":459,"activeCount":101},[],{"trials":461,"activeCount":101},[],{"trials":463,"activeCount":101},[],{"trials":465,"activeCount":164,"soonestReadout":338},[466,476,485],{"nctId":467,"briefTitle":468,"status":135,"phases":469,"primaryCompletion":470,"completion":471,"start":472,"enrollment":473,"conditions":474,"interventions":475},"NCT05029063","Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters",[91],"2026-12","2027-12","2022-10-05",1828,[21,18],[456],{"nctId":477,"briefTitle":478,"status":135,"phases":479,"primaryCompletion":338,"completion":338,"start":480,"enrollment":481,"conditions":482,"interventions":484},"NCT05920343","VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy",[90,91],"2024-11-04",120,[21,483],"Urologic Cancer",[456],{"nctId":486,"briefTitle":487,"status":109,"phases":488,"primaryCompletion":489,"completion":490,"start":491,"enrollment":492,"conditions":493,"interventions":495},"NCT03506815","Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines",[91],"2020-05-14","2020-06-14","2019-03-15",105,[141,494,18],"Central Venous Catheter Thrombosis",[456],{"trials":497,"activeCount":101},[],{"trials":499,"activeCount":101},[],{"intervention":501,"totalTrials":502,"cells":503},"Tranexamic Acid",4,{"EARLY_PHASE1":504,"PHASE1":506,"PHASE2":508,"PHASE3":510,"PHASE4":543,"NA":557},{"trials":505,"activeCount":101},[],{"trials":507,"activeCount":101},[],{"trials":509,"activeCount":101},[],{"trials":511,"activeCount":234,"soonestReadout":527},[512,523,533],{"nctId":513,"briefTitle":514,"status":109,"phases":515,"primaryCompletion":516,"completion":517,"start":518,"enrollment":519,"conditions":520,"interventions":522},"NCT01869413","Tranexamic Acid During Cystectomy Trial (TACT)",[90,91],"2021-01","2021-06","2013-06",354,[521],"Bladder Cancer",[501],{"nctId":524,"briefTitle":525,"status":135,"phases":526,"primaryCompletion":527,"completion":527,"start":528,"enrollment":529,"conditions":530,"interventions":532},"NCT04448184","Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial)",[91],"2027-02","2022-02-16",662,[531],"Hematologic Neoplasms",[501],{"nctId":534,"briefTitle":535,"status":109,"phases":536,"primaryCompletion":537,"completion":538,"start":539,"enrollment":540,"conditions":541,"interventions":542},"NCT02650791","Platelet Transfusion Requirements in Hematopoietic Transplantation Pilot Study",[91],"2019-06","2019-12","2016-10",100,[531],[501],{"trials":544,"activeCount":101},[545],{"nctId":546,"briefTitle":547,"status":548,"phases":549,"primaryCompletion":550,"completion":550,"start":551,"enrollment":552,"conditions":553,"interventions":556},"NCT02615366","Tranexamic Acid for Bleeding in Breast Surgery","UNKNOWN",[92],"2019-02","2016-02",800,[554,555],"Hematoma","Seroma",[501],{"trials":558,"activeCount":101},[],{"intervention":560,"totalTrials":502,"cells":561},"Prednisone",{"EARLY_PHASE1":562,"PHASE1":564,"PHASE2":566,"PHASE3":568,"PHASE4":609,"NA":623},{"trials":563,"activeCount":101},[],{"trials":565,"activeCount":101},[],{"trials":567,"activeCount":101},[],{"trials":569,"activeCount":234,"soonestReadout":587},[570,583,598],{"nctId":571,"briefTitle":572,"status":109,"phases":573,"primaryCompletion":574,"completion":575,"start":576,"enrollment":577,"conditions":578,"interventions":580},"NCT00789997","TNF-alpha Antagonists for AECOPD: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial",[90,91],"2011-08","2011-10","2008-11",81,[579],"COPD Exacerbation",[560,581,582],"Etanercept","levofloxacin",{"nctId":584,"briefTitle":585,"status":135,"phases":586,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":591,"interventions":594},"NCT06983821","Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)",[91],"2028-02","2029-02","2025-11-10",36,[592,593],"Granulomatosis With Polyangiitis","Microscopic Polyangiitis (MPA)",[595,596,560,597],"Cyclophosphamide","Standard of Care","Rituximab",{"nctId":599,"briefTitle":600,"status":601,"phases":602,"primaryCompletion":603,"completion":603,"start":604,"enrollment":101,"conditions":605,"interventions":608},"NCT00414414","A RCT of Prednisone as Adjunctive Therapy for Hospitalized Patients With Pulmonary TB and HIV Co-infection","WITHDRAWN",[91],"2009-06","2007-02",[606,607],"Tuberculosis","HIV Infections",[560],{"trials":610,"activeCount":101},[611],{"nctId":612,"briefTitle":613,"status":601,"phases":614,"primaryCompletion":615,"completion":615,"start":616,"enrollment":101,"conditions":617,"interventions":621},"NCT05101928","Ozurdex Monotherapy Trial",[92],"2025-01-15","2021-11-30",[618,619,620],"Uveitis, Posterior","Uveitis, Intermediate","Panuveitis",[622,560],"Ozurdex 0.7mg Ophthalmic Implant",{"trials":624,"activeCount":101},[],{"intervention":626,"totalTrials":234,"cells":627},"Lupron Depot",{"EARLY_PHASE1":628,"PHASE1":630,"PHASE2":632,"PHASE3":634,"PHASE4":646,"NA":648},{"trials":629,"activeCount":101},[],{"trials":631,"activeCount":101},[],{"trials":633,"activeCount":101},[],{"trials":635,"activeCount":234,"soonestReadout":640},[636],{"nctId":637,"briefTitle":638,"status":135,"phases":639,"primaryCompletion":640,"completion":641,"start":642,"enrollment":128,"conditions":643,"interventions":645},"NCT05169112","Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy",[91],"2026-11","2028-11","2023-03-06",[644],"Prostate Cancer",[626],{"trials":647,"activeCount":101},[],{"trials":649,"activeCount":101},[],{"intervention":651,"totalTrials":234,"cells":652},"Omeprazole 20 mg Oral",{"EARLY_PHASE1":653,"PHASE1":655,"PHASE2":657,"PHASE3":659,"PHASE4":672,"NA":674},{"trials":654,"activeCount":101},[],{"trials":656,"activeCount":101},[],{"trials":658,"activeCount":101},[],{"trials":660,"activeCount":234,"soonestReadout":471},[661],{"nctId":662,"briefTitle":663,"status":135,"phases":664,"primaryCompletion":471,"completion":665,"start":666,"enrollment":667,"conditions":668,"interventions":671},"NCT06393868","Reducing Gastrointestinal Bleeding With Proton Pump Inhibitor Therapy in Acute Venous Thromboembolism",[91],"2028-03","2024-11-06",360,[21,669,670],"Gastro Intestinal Bleeding","Blood Clot",[651],{"trials":673,"activeCount":101},[],{"trials":675,"activeCount":101},[],{"intervention":677,"totalTrials":234,"cells":678},"Colchicine 0.5 mg po",{"EARLY_PHASE1":679,"PHASE1":681,"PHASE2":683,"PHASE3":685,"PHASE4":696,"NA":698},{"trials":680,"activeCount":101},[],{"trials":682,"activeCount":101},[],{"trials":684,"activeCount":101},[],{"trials":686,"activeCount":234,"soonestReadout":691},[687],{"nctId":688,"briefTitle":689,"status":135,"phases":690,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":694,"interventions":695},"NCT06440694","Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial)",[91],"2027-12-01","2025-07-07",150,[21],[677],{"trials":697,"activeCount":101},[],{"trials":699,"activeCount":101},[],{"intervention":595,"totalTrials":234,"cells":701},{"EARLY_PHASE1":702,"PHASE1":704,"PHASE2":706,"PHASE3":708,"PHASE4":714,"NA":716},{"trials":703,"activeCount":101},[],{"trials":705,"activeCount":101},[],{"trials":707,"activeCount":101},[],{"trials":709,"activeCount":234,"soonestReadout":587},[710],{"nctId":584,"briefTitle":585,"status":135,"phases":711,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":712,"interventions":713},[91],[592,593],[595,596,560,597],{"trials":715,"activeCount":101},[],{"trials":717,"activeCount":101},[],{"intervention":596,"totalTrials":234,"cells":719},{"EARLY_PHASE1":720,"PHASE1":722,"PHASE2":724,"PHASE3":726,"PHASE4":732,"NA":734},{"trials":721,"activeCount":101},[],{"trials":723,"activeCount":101},[],{"trials":725,"activeCount":101},[],{"trials":727,"activeCount":234,"soonestReadout":587},[728],{"nctId":584,"briefTitle":585,"status":135,"phases":729,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":730,"interventions":731},[91],[592,593],[595,596,560,597],{"trials":733,"activeCount":101},[],{"trials":735,"activeCount":101},[],{"intervention":597,"totalTrials":234,"cells":737},{"EARLY_PHASE1":738,"PHASE1":740,"PHASE2":742,"PHASE3":744,"PHASE4":750,"NA":752},{"trials":739,"activeCount":101},[],{"trials":741,"activeCount":101},[],{"trials":743,"activeCount":101},[],{"trials":745,"activeCount":234,"soonestReadout":587},[746],{"nctId":584,"briefTitle":585,"status":135,"phases":747,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":748,"interventions":749},[91],[592,593],[595,596,560,597],{"trials":751,"activeCount":101},[],{"trials":753,"activeCount":101},[],{"intervention":755,"totalTrials":234,"cells":756},"Full dose rivaroxaban",{"EARLY_PHASE1":757,"PHASE1":759,"PHASE2":761,"PHASE3":763,"PHASE4":778,"NA":780},{"trials":758,"activeCount":101},[],{"trials":760,"activeCount":101},[],{"trials":762,"activeCount":101},[],{"trials":764,"activeCount":234,"soonestReadout":769},[765],{"nctId":766,"briefTitle":767,"status":135,"phases":768,"primaryCompletion":769,"completion":527,"start":770,"enrollment":771,"conditions":772,"interventions":776},"NCT06965998","A Pilot Trial Comparing Full Dose Rivaroxaban to Prophylactic Dose Rivaroxaban in Patients With Superficial Vein Thrombosis in the Leg",[90,91],"2026-08","2025-08-06",50,[773,774,775],"SVT","Thrombosis","Superficial Vein Thrombosis",[755,777],"Low dose rivaroxaban",{"trials":779,"activeCount":101},[],{"trials":781,"activeCount":101},[],{"intervention":777,"totalTrials":234,"cells":783},{"EARLY_PHASE1":784,"PHASE1":786,"PHASE2":788,"PHASE3":790,"PHASE4":796,"NA":798},{"trials":785,"activeCount":101},[],{"trials":787,"activeCount":101},[],{"trials":789,"activeCount":101},[],{"trials":791,"activeCount":234,"soonestReadout":769},[792],{"nctId":766,"briefTitle":767,"status":135,"phases":793,"primaryCompletion":769,"completion":527,"start":770,"enrollment":771,"conditions":794,"interventions":795},[90,91],[773,774,775],[755,777],{"trials":797,"activeCount":101},[],{"trials":799,"activeCount":101},[],{"intervention":801,"totalTrials":234,"cells":802},"Rosuvastatin Calcium",{"EARLY_PHASE1":803,"PHASE1":805,"PHASE2":807,"PHASE3":809,"PHASE4":822,"NA":824},{"trials":804,"activeCount":101},[],{"trials":806,"activeCount":101},[],{"trials":808,"activeCount":101},[],{"trials":810,"activeCount":234,"soonestReadout":815},[811],{"nctId":812,"briefTitle":813,"status":135,"phases":814,"primaryCompletion":815,"completion":816,"start":817,"enrollment":818,"conditions":819,"interventions":821},"NCT04319627","Statins for Venous Event Reduction in Patients With Venous Thromboembolism",[91],"2028-01","2028-04","2021-02-10",2700,[21,670,820],"Post Thrombotic Syndrome",[801],{"trials":823,"activeCount":101},[],{"trials":825,"activeCount":101},[],{"intervention":827,"totalTrials":234,"cells":828},"Human Allogenic Umbilical Cord Mesenchymal Stromal Cells",{"EARLY_PHASE1":829,"PHASE1":831,"PHASE2":833,"PHASE3":847,"PHASE4":849,"NA":851},{"trials":830,"activeCount":101},[],{"trials":832,"activeCount":101},[],{"trials":834,"activeCount":234,"soonestReadout":839},[835],{"nctId":836,"briefTitle":837,"status":201,"phases":838,"primaryCompletion":839,"completion":840,"start":841,"enrollment":842,"conditions":843,"interventions":846},"NCT07058025","Mesenchymal Stromal Cell Therapy to Prevent Bronchopulmonary Dysplasia in Extreme Preterm Infants",[90],"2028-09-30","2038-09-30","2025-10-01",168,[844,845],"Bronchopulmonary Dysplasia (BPD)","ELGAN (22-28SA)",[827],{"trials":848,"activeCount":101},[],{"trials":850,"activeCount":101},[],{"trials":852,"activeCount":101},[],{"intervention":854,"totalTrials":234,"cells":855},"Modafinil",{"EARLY_PHASE1":856,"PHASE1":858,"PHASE2":860,"PHASE3":874,"PHASE4":876,"NA":878},{"trials":857,"activeCount":101},[],{"trials":859,"activeCount":101},[],{"trials":861,"activeCount":234,"soonestReadout":866},[862],{"nctId":863,"briefTitle":864,"status":135,"phases":865,"primaryCompletion":866,"completion":665,"start":867,"enrollment":868,"conditions":869,"interventions":873},"NCT05333250","Modafinil to Improve Fatiguability",[89,90],"2027-10","2026-01-22",40,[870,871,872],"Cancer-related Cognitive Difficulties","Cancer-related Problem\u002FCondition","Fatigue",[854],{"trials":875,"activeCount":101},[],{"trials":877,"activeCount":101},[],{"trials":879,"activeCount":101},[],{"intervention":881,"totalTrials":234,"cells":882},"Allogeneic umbilical cord-derived human mesenchymal stromal cells",{"EARLY_PHASE1":883,"PHASE1":885,"PHASE2":887,"PHASE3":906,"PHASE4":908,"NA":910},{"trials":884,"activeCount":101},[],{"trials":886,"activeCount":101},[],{"trials":888,"activeCount":234,"soonestReadout":893},[889],{"nctId":890,"briefTitle":891,"status":135,"phases":892,"primaryCompletion":893,"completion":894,"start":895,"enrollment":896,"conditions":897,"interventions":905},"NCT05969275","Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic Shock",[90],"2026-09-30","2027-03-31","2024-02-14",296,[898,899,900,901,902,903,904],"Septic Shock","Sepsis","Pathologic Processes","Shock","Systemic Inflammatory Response Syndrome","Inflammation","Infections",[881],{"trials":907,"activeCount":101},[],{"trials":909,"activeCount":101},[],{"trials":911,"activeCount":101},[],{"intervention":913,"totalTrials":234,"cells":914},"Triptorelin",{"EARLY_PHASE1":915,"PHASE1":917,"PHASE2":919,"PHASE3":932,"PHASE4":934,"NA":936},{"trials":916,"activeCount":101},[],{"trials":918,"activeCount":101},[],{"trials":920,"activeCount":234,"soonestReadout":925},[921],{"nctId":922,"briefTitle":923,"status":135,"phases":924,"primaryCompletion":925,"completion":926,"start":927,"enrollment":928,"conditions":929,"interventions":931},"NCT05851547","Dose Escalation For INtraprostatic LEsions",[90],"2027-06","2028-06","2023-11-23",54,[930],"Prostatic Neoplasms",[913],{"trials":933,"activeCount":101},[],{"trials":935,"activeCount":101},[],{"trials":937,"activeCount":101},[],{"intervention":939,"totalTrials":234,"cells":940},"Hydroxychloroquine",{"EARLY_PHASE1":941,"PHASE1":943,"PHASE2":945,"PHASE3":957,"PHASE4":959,"NA":961},{"trials":942,"activeCount":101},[],{"trials":944,"activeCount":101},[],{"trials":946,"activeCount":234,"soonestReadout":951},[947],{"nctId":948,"briefTitle":949,"status":201,"phases":950,"primaryCompletion":951,"completion":952,"start":953,"enrollment":868,"conditions":954,"interventions":956},"NCT06816810","A Study to Evaluate Efficacy, Safety and Tolerability of Hydroxychloroquine in Subjects With Parkinson's Disease",[90],"2026-09","2027-03","2025-03",[955],"Parkinson&Amp;#39;s Disease",[939],{"trials":958,"activeCount":101},[],{"trials":960,"activeCount":101},[],{"trials":962,"activeCount":101},[],{"intervention":62,"totalTrials":234,"cells":964},{"EARLY_PHASE1":965,"PHASE1":967,"PHASE2":969,"PHASE3":979,"PHASE4":981,"NA":983},{"trials":966,"activeCount":101},[],{"trials":968,"activeCount":101},[],{"trials":970,"activeCount":234,"soonestReadout":61},[971],{"nctId":59,"briefTitle":60,"status":135,"phases":972,"primaryCompletion":61,"completion":973,"start":974,"enrollment":19,"conditions":975,"interventions":978},[89,90],"2025-06","2024-01-08",[976,977],"Depression, Anxiety","Distress, Emotional",[62],{"trials":980,"activeCount":101},[],{"trials":982,"activeCount":101},[],{"trials":984,"activeCount":101},[],{"intervention":986,"totalTrials":234,"cells":987},"Cold-stored platelet concentrate",{"EARLY_PHASE1":988,"PHASE1":990,"PHASE2":992,"PHASE3":1004,"PHASE4":1006,"NA":1008},{"trials":989,"activeCount":101},[],{"trials":991,"activeCount":101},[],{"trials":993,"activeCount":234,"soonestReadout":998},[994],{"nctId":995,"briefTitle":996,"status":135,"phases":997,"primaryCompletion":998,"completion":999,"start":1000,"enrollment":771,"conditions":1001,"interventions":1003},"NCT05820126","Cold Versus Room Temperature Storage of Platelets for Bleeding in Hematologic Malignancy - a Pilot Trial",[90],"2026-06-01","2026-12-31","2025-05-16",[1002],"Hematologic Malignancy",[986],{"trials":1005,"activeCount":101},[],{"trials":1007,"activeCount":101},[],{"trials":1009,"activeCount":101},[],{"intervention":57,"totalTrials":234,"cells":1011},{"EARLY_PHASE1":1012,"PHASE1":1014,"PHASE2":1016,"PHASE3":1026,"PHASE4":1028,"NA":1030},{"trials":1013,"activeCount":101},[],{"trials":1015,"activeCount":101},[],{"trials":1017,"activeCount":234,"soonestReadout":56},[1018],{"nctId":54,"briefTitle":55,"status":286,"phases":1019,"primaryCompletion":56,"completion":973,"start":1020,"enrollment":771,"conditions":1021,"interventions":1023},[90],"2024-05-30",[1022],"Complex Regional Pain Syndromes",[57,1024,1025],"Saline","Bupivacaine",{"trials":1027,"activeCount":101},[],{"trials":1029,"activeCount":101},[],{"trials":1031,"activeCount":101},[],{"intervention":1024,"totalTrials":234,"cells":1033},{"EARLY_PHASE1":1034,"PHASE1":1036,"PHASE2":1038,"PHASE3":1044,"PHASE4":1046,"NA":1048},{"trials":1035,"activeCount":101},[],{"trials":1037,"activeCount":101},[],{"trials":1039,"activeCount":234,"soonestReadout":56},[1040],{"nctId":54,"briefTitle":55,"status":286,"phases":1041,"primaryCompletion":56,"completion":973,"start":1020,"enrollment":771,"conditions":1042,"interventions":1043},[90],[1022],[57,1024,1025],{"trials":1045,"activeCount":101},[],{"trials":1047,"activeCount":101},[],{"trials":1049,"activeCount":101},[],{"intervention":1051,"totalTrials":234,"cells":1052},"CLIC-1901",{"EARLY_PHASE1":1053,"PHASE1":1055,"PHASE2":1057,"PHASE3":1072,"PHASE4":1074,"NA":1076},{"trials":1054,"activeCount":101},[],{"trials":1056,"activeCount":101},[],{"trials":1058,"activeCount":234,"soonestReadout":1063},[1059],{"nctId":1060,"briefTitle":1061,"status":135,"phases":1062,"primaryCompletion":1063,"completion":1064,"start":1065,"enrollment":1066,"conditions":1067,"interventions":1071},"NCT03765177","CLIC-1901 for the Treatment of Patients With Relapsed\u002FRefractory CD19 Positive Hematologic Malignancies",[89,90],"2027-01","2042-06-30","2019-10-16",60,[1068,1069,1070],"Acute Lymphoblastic Leukemia","Non-Hodgkin's Lymphoma","Chronic Lymphocytic Leukemia",[1051],{"trials":1073,"activeCount":101},[],{"trials":1075,"activeCount":101},[],{"trials":1077,"activeCount":101},[],{"intervention":42,"totalTrials":234,"cells":1079},{"EARLY_PHASE1":1080,"PHASE1":1082,"PHASE2":1084,"PHASE3":1096,"PHASE4":1098,"NA":1100},{"trials":1081,"activeCount":101},[],{"trials":1083,"activeCount":101},[],{"trials":1085,"activeCount":234,"soonestReadout":41},[1086],{"nctId":39,"briefTitle":40,"status":286,"phases":1087,"primaryCompletion":41,"completion":1088,"start":1089,"enrollment":1090,"conditions":1091,"interventions":1093},[90],"2029-11","2013-07-19",47,[1092],"Anterior Wall Myocardial Infarction",[42,1094,1095],"Autologous EPCs","Autologous EPCs Transfected with human eNOS",{"trials":1097,"activeCount":101},[],{"trials":1099,"activeCount":101},[],{"trials":1101,"activeCount":101},[],{"intervention":1094,"totalTrials":234,"cells":1103},{"EARLY_PHASE1":1104,"PHASE1":1106,"PHASE2":1108,"PHASE3":1114,"PHASE4":1116,"NA":1118},{"trials":1105,"activeCount":101},[],{"trials":1107,"activeCount":101},[],{"trials":1109,"activeCount":234,"soonestReadout":41},[1110],{"nctId":39,"briefTitle":40,"status":286,"phases":1111,"primaryCompletion":41,"completion":1088,"start":1089,"enrollment":1090,"conditions":1112,"interventions":1113},[90],[1092],[42,1094,1095],{"trials":1115,"activeCount":101},[],{"trials":1117,"activeCount":101},[],{"trials":1119,"activeCount":101},[],{"intervention":1095,"totalTrials":234,"cells":1121},{"EARLY_PHASE1":1122,"PHASE1":1124,"PHASE2":1126,"PHASE3":1132,"PHASE4":1134,"NA":1136},{"trials":1123,"activeCount":101},[],{"trials":1125,"activeCount":101},[],{"trials":1127,"activeCount":234,"soonestReadout":41},[1128],{"nctId":39,"briefTitle":40,"status":286,"phases":1129,"primaryCompletion":41,"completion":1088,"start":1089,"enrollment":1090,"conditions":1130,"interventions":1131},[90],[1092],[42,1094,1095],{"trials":1133,"activeCount":101},[],{"trials":1135,"activeCount":101},[],{"trials":1137,"activeCount":101},[],{"intervention":1025,"totalTrials":168,"cells":1139},{"EARLY_PHASE1":1140,"PHASE1":1142,"PHASE2":1144,"PHASE3":1150,"PHASE4":1152,"NA":1167},{"trials":1141,"activeCount":101},[],{"trials":1143,"activeCount":101},[],{"trials":1145,"activeCount":234,"soonestReadout":56},[1146],{"nctId":54,"briefTitle":55,"status":286,"phases":1147,"primaryCompletion":56,"completion":973,"start":1020,"enrollment":771,"conditions":1148,"interventions":1149},[90],[1022],[57,1024,1025],{"trials":1151,"activeCount":101},[],{"trials":1153,"activeCount":101},[1154],{"nctId":1155,"briefTitle":1156,"status":548,"phases":1157,"primaryCompletion":1158,"completion":1158,"start":1159,"enrollment":1160,"conditions":1161,"interventions":1164},"NCT04257682","Regional Anesthesia in Total Hip and Knee Arthroplasty",[92],"2023-02","2022-09",135,[1162,1163],"Knee Osteoarthritis","Hip Osteoarthritis",[1025,1165,1166],"Ropivacaine","Mepivacaine",{"trials":1168,"activeCount":101},[1169],{"nctId":1170,"briefTitle":1171,"status":548,"phases":1172,"primaryCompletion":1173,"completion":1174,"start":1175,"enrollment":492,"conditions":1176,"interventions":1180},"NCT03871478","Comparing the Efficacy of Local Anesthetics in Mohs Surgery",[93],"2021-03-31","2021-06-14","2019-10-01",[1177,1025,1178,1179],"Lidocaine","Mohs Surgery","Anesthetic",[1177,1025,1181],"Lidocaine and Bupivacaine",{"intervention":67,"totalTrials":234,"cells":1183},{"EARLY_PHASE1":1184,"PHASE1":1186,"PHASE2":1194,"PHASE3":1196,"PHASE4":1198,"NA":1200},{"trials":1185,"activeCount":101},[],{"trials":1187,"activeCount":234,"soonestReadout":66},[1188],{"nctId":64,"briefTitle":65,"status":286,"phases":1189,"primaryCompletion":66,"completion":66,"start":1190,"enrollment":234,"conditions":1191,"interventions":1193},[89],"2024-02-22",[1192],"Periprosthetic Joint Infection",[67],{"trials":1195,"activeCount":101},[],{"trials":1197,"activeCount":101},[],{"trials":1199,"activeCount":101},[],{"trials":1201,"activeCount":101},[],{"intervention":47,"totalTrials":234,"cells":1203},{"EARLY_PHASE1":1204,"PHASE1":1206,"PHASE2":1215,"PHASE3":1217,"PHASE4":1219,"NA":1221},{"trials":1205,"activeCount":101},[],{"trials":1207,"activeCount":234,"soonestReadout":46},[1208],{"nctId":44,"briefTitle":45,"status":286,"phases":1209,"primaryCompletion":46,"completion":1210,"start":1211,"enrollment":31,"conditions":1212,"interventions":1214},[89],"2033-11-06","2022-10-17",[1213],"Bronchopulmonary Dysplasia",[47],{"trials":1216,"activeCount":101},[],{"trials":1218,"activeCount":101},[],{"trials":1220,"activeCount":101},[],{"trials":1222,"activeCount":101},[],{"intervention":1224,"totalTrials":168,"cells":1225},"Nicotine Replacement Therapy",{"EARLY_PHASE1":1226,"PHASE1":1228,"PHASE2":1230,"PHASE3":1232,"PHASE4":1247,"NA":1249},{"trials":1227,"activeCount":101},[],{"trials":1229,"activeCount":101},[],{"trials":1231,"activeCount":101},[],{"trials":1233,"activeCount":101},[1234],{"nctId":1235,"briefTitle":1236,"status":548,"phases":1237,"primaryCompletion":1238,"completion":1239,"start":1240,"enrollment":1241,"conditions":1242,"interventions":1245},"NCT01800019","The Canadian HIV Quit Smoking Trial: Tackling the Co-morbidities of Depression and Cardiovascular Disease in HIV+ Smokers",[91],"2017-12","2019-01","2014-01",256,[1243,1244],"HIV","Smoking Cessation",[1224,1246],"Varenicline",{"trials":1248,"activeCount":101},[],{"trials":1250,"activeCount":234,"soonestReadout":952},[1251,1263],{"nctId":1252,"briefTitle":1253,"status":109,"phases":1254,"primaryCompletion":1255,"completion":1255,"start":1256,"enrollment":1257,"conditions":1258,"interventions":1262},"NCT03626064","The PROMPT Pilot Study",[93],"2017-03","2014-06",80,[1259,1260,1261],"Tobacco Use Disorder","Tobacco Dependence","Tobacco Use Cessation",[1224],{"nctId":1264,"briefTitle":1265,"status":192,"phases":1266,"primaryCompletion":952,"completion":952,"start":1267,"enrollment":1268,"conditions":1269,"interventions":1273},"NCT03249428","Cytisine vs Nicotine Replacement Therapy",[93],"2025-11-04",200,[1260,1270,1271,1272],"COPD Asthma","Mental Illness","Substance Use",[1274,1275],"Cytisine","Nicotine replacement therapy",{"intervention":1274,"totalTrials":234,"cells":1277},{"EARLY_PHASE1":1278,"PHASE1":1280,"PHASE2":1282,"PHASE3":1284,"PHASE4":1286,"NA":1288},{"trials":1279,"activeCount":101},[],{"trials":1281,"activeCount":101},[],{"trials":1283,"activeCount":101},[],{"trials":1285,"activeCount":101},[],{"trials":1287,"activeCount":101},[],{"trials":1289,"activeCount":234,"soonestReadout":952},[1290],{"nctId":1264,"briefTitle":1265,"status":192,"phases":1291,"primaryCompletion":952,"completion":952,"start":1267,"enrollment":1268,"conditions":1292,"interventions":1293},[93],[1260,1270,1271,1272],[1274,1275],{"intervention":1295,"totalTrials":164,"cells":1296},"Levofloxacin",{"EARLY_PHASE1":1297,"PHASE1":1299,"PHASE2":1301,"PHASE3":1303,"PHASE4":1309,"NA":1322},{"trials":1298,"activeCount":101},[],{"trials":1300,"activeCount":101},[],{"trials":1302,"activeCount":101},[],{"trials":1304,"activeCount":101},[1305],{"nctId":571,"briefTitle":572,"status":109,"phases":1306,"primaryCompletion":574,"completion":575,"start":576,"enrollment":577,"conditions":1307,"interventions":1308},[90,91],[579],[560,581,582],{"trials":1310,"activeCount":101},[1311],{"nctId":1312,"briefTitle":1313,"status":109,"phases":1314,"primaryCompletion":1315,"completion":1315,"start":1316,"enrollment":1317,"conditions":1318,"interventions":1321},"NCT01353339","Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A Pilot Study",[92],"2014-02-25","2011-12-01",154,[1319,1320],"Disease Due to BK Polyomavirus","Kidney Transplant Infection",[1295],{"trials":1323,"activeCount":101},[],{"intervention":1325,"totalTrials":164,"cells":1326},"Filgrastim",{"EARLY_PHASE1":1327,"PHASE1":1329,"PHASE2":1340,"PHASE3":1342,"PHASE4":1344,"NA":1357},{"trials":1328,"activeCount":101},[],{"trials":1330,"activeCount":101},[1331],{"nctId":1332,"briefTitle":1333,"status":548,"phases":1334,"primaryCompletion":1335,"completion":1335,"start":1336,"enrollment":19,"conditions":1337,"interventions":1339},"NCT00809549","Study to Determine The Effect of a Drug Called Neupogen on Stroke Recovery",[89],"2013-04","2006-07",[1338],"Ischemic Stroke",[1325],{"trials":1341,"activeCount":101},[],{"trials":1343,"activeCount":101},[],{"trials":1345,"activeCount":101},[1346],{"nctId":1347,"briefTitle":1348,"status":109,"phases":1349,"primaryCompletion":1350,"completion":1351,"start":1352,"enrollment":1353,"conditions":1354,"interventions":1355},"NCT04781959","A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant\u002FAdjuvant Chemotherapy",[92],"2023-02-23","2023-09-28","2021-06-09",233,[342],[1325,1356],"Pegfilgrastim",{"trials":1358,"activeCount":101},[],{"intervention":1360,"totalTrials":164,"cells":1361},"Neupogen",{"EARLY_PHASE1":1362,"PHASE1":1364,"PHASE2":1366,"PHASE3":1368,"PHASE4":1370,"NA":1391},{"trials":1363,"activeCount":101},[],{"trials":1365,"activeCount":101},[],{"trials":1367,"activeCount":101},[],{"trials":1369,"activeCount":101},[],{"trials":1371,"activeCount":101},[1372,1381],{"nctId":1373,"briefTitle":1374,"status":109,"phases":1375,"primaryCompletion":550,"completion":550,"start":1376,"enrollment":1377,"conditions":1378,"interventions":1380},"NCT02816164","A Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Febrile Neutropenia",[92],"2016-09",324,[1379],"Early Stage Breast Cancer",[1360],{"nctId":1382,"briefTitle":1383,"status":109,"phases":1384,"primaryCompletion":1385,"completion":1386,"start":1376,"enrollment":1387,"conditions":1388,"interventions":1389},"NCT02816112","Granulocyte-colony Stimulating Factors or Antibiotics for Primary Prophylaxis for Febrile Neutropenia",[92],"2020-03","2020-04",458,[1379],[1390,1360],"Ciprofloxacin",{"trials":1392,"activeCount":101},[],{"intervention":1390,"totalTrials":164,"cells":1394},{"EARLY_PHASE1":1395,"PHASE1":1397,"PHASE2":1399,"PHASE3":1401,"PHASE4":1403,"NA":1419},{"trials":1396,"activeCount":101},[],{"trials":1398,"activeCount":101},[],{"trials":1400,"activeCount":101},[],{"trials":1402,"activeCount":101},[],{"trials":1404,"activeCount":101},[1405,1409],{"nctId":1382,"briefTitle":1383,"status":109,"phases":1406,"primaryCompletion":1385,"completion":1386,"start":1376,"enrollment":1387,"conditions":1407,"interventions":1408},[92],[1379],[1390,1360],{"nctId":1410,"briefTitle":1411,"status":109,"phases":1412,"primaryCompletion":1413,"completion":1413,"start":1414,"enrollment":1415,"conditions":1416,"interventions":1417},"NCT02173262","REaCT Integrated Consent Model to Compare Two Standard of Care Regimens",[92],"2017-09","2014-08",142,[15],[1418,1390],"G-CSF",{"trials":1420,"activeCount":101},[],{"intervention":1422,"totalTrials":164,"cells":1423},"Pamidronate",{"EARLY_PHASE1":1424,"PHASE1":1426,"PHASE2":1428,"PHASE3":1430,"PHASE4":1432,"NA":1456},{"trials":1425,"activeCount":101},[],{"trials":1427,"activeCount":101},[],{"trials":1429,"activeCount":101},[],{"trials":1431,"activeCount":101},[],{"trials":1433,"activeCount":101},[1434,1446],{"nctId":1435,"briefTitle":1436,"status":109,"phases":1437,"primaryCompletion":1438,"completion":1386,"start":1439,"enrollment":1440,"conditions":1441,"interventions":1443},"NCT02721433","4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases",[92],"2019-09","2016-08",263,[15,644,1442],"Metastasis",[1422,1444,1445],"Denosumab","Zoledronate",{"nctId":1447,"briefTitle":1448,"status":109,"phases":1449,"primaryCompletion":1450,"completion":1450,"start":1451,"enrollment":1452,"conditions":1453,"interventions":1454},"NCT01907880","The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast Cancer",[92],"2016-01","2012-08",74,[15],[1422,1455],"Zoledronic acid",{"trials":1457,"activeCount":101},[],{"intervention":1445,"totalTrials":164,"cells":1459},{"EARLY_PHASE1":1460,"PHASE1":1462,"PHASE2":1464,"PHASE3":1466,"PHASE4":1468,"NA":1484},{"trials":1461,"activeCount":101},[],{"trials":1463,"activeCount":101},[],{"trials":1465,"activeCount":101},[],{"trials":1467,"activeCount":101},[],{"trials":1469,"activeCount":101},[1470,1474],{"nctId":1435,"briefTitle":1436,"status":109,"phases":1471,"primaryCompletion":1438,"completion":1386,"start":1439,"enrollment":1440,"conditions":1472,"interventions":1473},[92],[15,644,1442],[1422,1444,1445],{"nctId":1475,"briefTitle":1476,"status":109,"phases":1477,"primaryCompletion":1478,"completion":1479,"start":1480,"enrollment":1481,"conditions":1482,"interventions":1483},"NCT03664687","Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL)",[92],"2020-04-02","2025-03-28","2018-10-31",211,[342],[1445],{"trials":1485,"activeCount":101},[],{"intervention":1487,"totalTrials":234,"cells":1488},"Intravenous Saline",{"EARLY_PHASE1":1489,"PHASE1":1491,"PHASE2":1493,"PHASE3":1495,"PHASE4":1497,"NA":1509},{"trials":1490,"activeCount":101},[],{"trials":1492,"activeCount":101},[],{"trials":1494,"activeCount":101},[],{"trials":1496,"activeCount":101},[],{"trials":1498,"activeCount":101},[1499],{"nctId":1500,"briefTitle":1501,"status":601,"phases":1502,"primaryCompletion":1503,"completion":1504,"start":1505,"enrollment":101,"conditions":1506,"interventions":1507},"NCT02084771","Oral Salt and Water to Prevent Contrast Nephropathy",[92],"2015-12","2016-06","2014-10",[409],[1487,1508],"Oral Salt and Water",{"trials":1510,"activeCount":101},[],{"intervention":1508,"totalTrials":234,"cells":1512},{"EARLY_PHASE1":1513,"PHASE1":1515,"PHASE2":1517,"PHASE3":1519,"PHASE4":1521,"NA":1527},{"trials":1514,"activeCount":101},[],{"trials":1516,"activeCount":101},[],{"trials":1518,"activeCount":101},[],{"trials":1520,"activeCount":101},[],{"trials":1522,"activeCount":101},[1523],{"nctId":1500,"briefTitle":1501,"status":601,"phases":1524,"primaryCompletion":1503,"completion":1504,"start":1505,"enrollment":101,"conditions":1525,"interventions":1526},[92],[409],[1487,1508],{"trials":1528,"activeCount":101},[],{"intervention":1530,"totalTrials":234,"cells":1531},"Raltegravir standard dosage of 1200 mg (two 600 mg tablets) orally once daily.",{"EARLY_PHASE1":1532,"PHASE1":1534,"PHASE2":1536,"PHASE3":1538,"PHASE4":1540,"NA":1553},{"trials":1533,"activeCount":101},[],{"trials":1535,"activeCount":101},[],{"trials":1537,"activeCount":101},[],{"trials":1539,"activeCount":101},[],{"trials":1541,"activeCount":101},[1542],{"nctId":1543,"briefTitle":1544,"status":548,"phases":1545,"primaryCompletion":1546,"completion":1547,"start":1548,"enrollment":28,"conditions":1549,"interventions":1551},"NCT04258475","The Influence of Concurrent Oral Calcium Carbonate Supplementation on Steady State Pharmacokinetics of Oral Raltegravir.",[92],"2024-06-15","2025-01-01","2020-12-09",[1550],"Calcium Supplementation in HIV Patients Using Raltegravir",[1530,1552],"Calcium carbonate antacid",{"trials":1554,"activeCount":101},[],{"intervention":1552,"totalTrials":234,"cells":1556},{"EARLY_PHASE1":1557,"PHASE1":1559,"PHASE2":1561,"PHASE3":1563,"PHASE4":1565,"NA":1571},{"trials":1558,"activeCount":101},[],{"trials":1560,"activeCount":101},[],{"trials":1562,"activeCount":101},[],{"trials":1564,"activeCount":101},[],{"trials":1566,"activeCount":101},[1567],{"nctId":1543,"briefTitle":1544,"status":548,"phases":1568,"primaryCompletion":1546,"completion":1547,"start":1548,"enrollment":28,"conditions":1569,"interventions":1570},[92],[1550],[1530,1552],{"trials":1572,"activeCount":101},[],{"intervention":1574,"totalTrials":234,"cells":1575},"Endocrine Therapy and Radiotherapy",{"EARLY_PHASE1":1576,"PHASE1":1578,"PHASE2":1580,"PHASE3":1582,"PHASE4":1584,"NA":1595},{"trials":1577,"activeCount":101},[],{"trials":1579,"activeCount":101},[],{"trials":1581,"activeCount":101},[],{"trials":1583,"activeCount":101},[],{"trials":1585,"activeCount":101},[1586],{"nctId":1587,"briefTitle":1588,"status":109,"phases":1589,"primaryCompletion":1352,"completion":1590,"start":1591,"enrollment":1592,"conditions":1593,"interventions":1594},"NCT03948568","Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT)",[92],"2022-04-09","2019-09-17",262,[342],[1574],{"trials":1596,"activeCount":101},[],{"intervention":1598,"totalTrials":234,"cells":1599},"16,5% Cutaquig",{"EARLY_PHASE1":1600,"PHASE1":1602,"PHASE2":1604,"PHASE3":1606,"PHASE4":1608,"NA":1620},{"trials":1601,"activeCount":101},[],{"trials":1603,"activeCount":101},[],{"trials":1605,"activeCount":101},[],{"trials":1607,"activeCount":101},[],{"trials":1609,"activeCount":101},[1610],{"nctId":1611,"briefTitle":1612,"status":548,"phases":1613,"primaryCompletion":1614,"completion":1614,"start":1615,"enrollment":196,"conditions":1616,"interventions":1619},"NCT03677557","Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment",[92],"2021-08-31","2018-09-19",[1617,1618],"Primary Immunodeficiency Disease","Secondary Immunodeficiency",[1598],{"trials":1621,"activeCount":101},[],{"intervention":1623,"totalTrials":234,"cells":1624},"Upadacitinib",{"EARLY_PHASE1":1625,"PHASE1":1627,"PHASE2":1629,"PHASE3":1631,"PHASE4":1633,"NA":1645},{"trials":1626,"activeCount":101},[],{"trials":1628,"activeCount":101},[],{"trials":1630,"activeCount":101},[],{"trials":1632,"activeCount":101},[],{"trials":1634,"activeCount":101},[1635],{"nctId":1636,"briefTitle":1637,"status":548,"phases":1638,"primaryCompletion":1639,"completion":1639,"start":1640,"enrollment":868,"conditions":1641,"interventions":1643},"NCT05153200","Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.",[92],"2023-06","2022-01",[1642],"Rheumatoid Arthritis",[1623,1644],"Adalimumab",{"trials":1646,"activeCount":101},[],{"intervention":1644,"totalTrials":234,"cells":1648},{"EARLY_PHASE1":1649,"PHASE1":1651,"PHASE2":1653,"PHASE3":1655,"PHASE4":1657,"NA":1663},{"trials":1650,"activeCount":101},[],{"trials":1652,"activeCount":101},[],{"trials":1654,"activeCount":101},[],{"trials":1656,"activeCount":101},[],{"trials":1658,"activeCount":101},[1659],{"nctId":1636,"briefTitle":1637,"status":548,"phases":1660,"primaryCompletion":1639,"completion":1639,"start":1640,"enrollment":868,"conditions":1661,"interventions":1662},[92],[1642],[1623,1644],{"trials":1664,"activeCount":101},[],{"intervention":1666,"totalTrials":234,"cells":1667},"ABT450r-ABT267-ABT333 +\u002F- Ribavirin",{"EARLY_PHASE1":1668,"PHASE1":1670,"PHASE2":1672,"PHASE3":1674,"PHASE4":1676,"NA":1689},{"trials":1669,"activeCount":101},[],{"trials":1671,"activeCount":101},[],{"trials":1673,"activeCount":101},[],{"trials":1675,"activeCount":101},[],{"trials":1677,"activeCount":101},[1678],{"nctId":1679,"briefTitle":1680,"status":109,"phases":1681,"primaryCompletion":1682,"completion":1683,"start":1684,"enrollment":1685,"conditions":1686,"interventions":1688},"NCT02734173","Pilot HCV Direct Acting Antiviral Therapy and Metabolism",[92],"2017-02","2017-05-31","2015-07",24,[1687],"Hepatitis C",[1666],{"trials":1690,"activeCount":101},[],{"intervention":1692,"totalTrials":234,"cells":1693},"Itraconazole",{"EARLY_PHASE1":1694,"PHASE1":1696,"PHASE2":1698,"PHASE3":1700,"PHASE4":1702,"NA":1715},{"trials":1695,"activeCount":101},[],{"trials":1697,"activeCount":101},[],{"trials":1699,"activeCount":101},[],{"trials":1701,"activeCount":101},[],{"trials":1703,"activeCount":101},[1704],{"nctId":1705,"briefTitle":1706,"status":109,"phases":1707,"primaryCompletion":1708,"completion":1709,"start":1710,"enrollment":1711,"conditions":1712,"interventions":1714},"NCT00528190","Treatment of Aspergillus Fumigatus (a Fungal Infection) in Patients With Cystic Fibrosis",[92],"2010-08","2011-05","2007-10",35,[1713],"Cystic Fibrosis",[1692],{"trials":1716,"activeCount":101},[],{"intervention":1718,"totalTrials":234,"cells":1719},"Human Plasma",{"EARLY_PHASE1":1720,"PHASE1":1722,"PHASE2":1724,"PHASE3":1726,"PHASE4":1728,"NA":1743},{"trials":1721,"activeCount":101},[],{"trials":1723,"activeCount":101},[],{"trials":1725,"activeCount":101},[],{"trials":1727,"activeCount":101},[],{"trials":1729,"activeCount":101},[1730],{"nctId":1731,"briefTitle":1732,"status":601,"phases":1733,"primaryCompletion":1734,"completion":1735,"start":1736,"enrollment":101,"conditions":1737,"interventions":1742},"NCT01221389","Study Using Plasma for Patients Requiring Emergency Surgery",[92],"2012-12","2013-03","2012-03",[1738,1739,1740,189,1741],"Hemorrhagic Shock","Blood Coagulation Disorders","Blood Products","Ruptured AAA",[1718],{"trials":1744,"activeCount":101},[],{"intervention":1746,"totalTrials":234,"cells":1747},"Standard Dose Ibuprofen",{"EARLY_PHASE1":1748,"PHASE1":1750,"PHASE2":1752,"PHASE3":1754,"PHASE4":1756,"NA":1769},{"trials":1749,"activeCount":101},[],{"trials":1751,"activeCount":101},[],{"trials":1753,"activeCount":101},[],{"trials":1755,"activeCount":101},[],{"trials":1757,"activeCount":101},[1758],{"nctId":1759,"briefTitle":1760,"status":548,"phases":1761,"primaryCompletion":1762,"completion":1763,"start":1764,"enrollment":196,"conditions":1765,"interventions":1767},"NCT05325177","PDA Treatment With Ibuprofen and Changes in Tissue Oxygenation.",[92],"2024-12-01","2024-12-31","2022-06-01",[1766],"Patent Ductus Arteriosus After Premature Birth",[1746,1768],"High Dose Ibuprofen",{"trials":1770,"activeCount":101},[],{"intervention":1768,"totalTrials":234,"cells":1772},{"EARLY_PHASE1":1773,"PHASE1":1775,"PHASE2":1777,"PHASE3":1779,"PHASE4":1781,"NA":1787},{"trials":1774,"activeCount":101},[],{"trials":1776,"activeCount":101},[],{"trials":1778,"activeCount":101},[],{"trials":1780,"activeCount":101},[],{"trials":1782,"activeCount":101},[1783],{"nctId":1759,"briefTitle":1760,"status":548,"phases":1784,"primaryCompletion":1762,"completion":1763,"start":1764,"enrollment":196,"conditions":1785,"interventions":1786},[92],[1766],[1746,1768],{"trials":1788,"activeCount":101},[],{"intervention":1790,"totalTrials":234,"cells":1791},"Vernakalant",{"EARLY_PHASE1":1792,"PHASE1":1794,"PHASE2":1796,"PHASE3":1798,"PHASE4":1800,"NA":1812},{"trials":1793,"activeCount":101},[],{"trials":1795,"activeCount":101},[],{"trials":1797,"activeCount":101},[],{"trials":1799,"activeCount":101},[],{"trials":1801,"activeCount":101},[1802],{"nctId":1803,"briefTitle":1804,"status":109,"phases":1805,"primaryCompletion":1806,"completion":666,"start":1807,"enrollment":1808,"conditions":1809,"interventions":1810},"NCT04485195","RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department",[92],"2024-09-15","2021-06-17",350,[152],[1790,1811],"Procainamide",{"trials":1813,"activeCount":101},[],{"intervention":1811,"totalTrials":234,"cells":1815},{"EARLY_PHASE1":1816,"PHASE1":1818,"PHASE2":1820,"PHASE3":1822,"PHASE4":1824,"NA":1830},{"trials":1817,"activeCount":101},[],{"trials":1819,"activeCount":101},[],{"trials":1821,"activeCount":101},[],{"trials":1823,"activeCount":101},[],{"trials":1825,"activeCount":101},[1826],{"nctId":1803,"briefTitle":1804,"status":109,"phases":1827,"primaryCompletion":1806,"completion":666,"start":1807,"enrollment":1808,"conditions":1828,"interventions":1829},[92],[152],[1790,1811],{"trials":1831,"activeCount":101},[],{"intervention":260,"totalTrials":234,"cells":1833},{"EARLY_PHASE1":1834,"PHASE1":1836,"PHASE2":1838,"PHASE3":1840,"PHASE4":1842,"NA":1848},{"trials":1835,"activeCount":101},[],{"trials":1837,"activeCount":101},[],{"trials":1839,"activeCount":101},[],{"trials":1841,"activeCount":101},[],{"trials":1843,"activeCount":101},[1844],{"nctId":251,"briefTitle":252,"status":109,"phases":1845,"primaryCompletion":254,"completion":254,"start":255,"enrollment":256,"conditions":1846,"interventions":1847},[92],[258],[238,260],{"trials":1849,"activeCount":101},[],{"intervention":1851,"totalTrials":234,"cells":1852},"Ringer's lactate",{"EARLY_PHASE1":1853,"PHASE1":1855,"PHASE2":1857,"PHASE3":1859,"PHASE4":1861,"NA":1874},{"trials":1854,"activeCount":101},[],{"trials":1856,"activeCount":101},[],{"trials":1858,"activeCount":101},[],{"trials":1860,"activeCount":101},[],{"trials":1862,"activeCount":101},[1863],{"nctId":1864,"briefTitle":1865,"status":109,"phases":1866,"primaryCompletion":1867,"completion":1867,"start":1868,"enrollment":1869,"conditions":1870,"interventions":1872},"NCT04512950","Crystalloid FLUID Choices for Resuscitation of Hospitalized Patients",[92],"2020-06-13","2016-08-15",43626,[1871],"Fluid Therapy",[1851,1873],"0.9% saline",{"trials":1875,"activeCount":101},[],{"intervention":1873,"totalTrials":234,"cells":1877},{"EARLY_PHASE1":1878,"PHASE1":1880,"PHASE2":1882,"PHASE3":1884,"PHASE4":1886,"NA":1892},{"trials":1879,"activeCount":101},[],{"trials":1881,"activeCount":101},[],{"trials":1883,"activeCount":101},[],{"trials":1885,"activeCount":101},[],{"trials":1887,"activeCount":101},[1888],{"nctId":1864,"briefTitle":1865,"status":109,"phases":1889,"primaryCompletion":1867,"completion":1867,"start":1868,"enrollment":1869,"conditions":1890,"interventions":1891},[92],[1871],[1851,1873],{"trials":1893,"activeCount":101},[],{"intervention":1418,"totalTrials":234,"cells":1895},{"EARLY_PHASE1":1896,"PHASE1":1898,"PHASE2":1900,"PHASE3":1902,"PHASE4":1904,"NA":1910},{"trials":1897,"activeCount":101},[],{"trials":1899,"activeCount":101},[],{"trials":1901,"activeCount":101},[],{"trials":1903,"activeCount":101},[],{"trials":1905,"activeCount":101},[1906],{"nctId":1410,"briefTitle":1411,"status":109,"phases":1907,"primaryCompletion":1413,"completion":1413,"start":1414,"enrollment":1415,"conditions":1908,"interventions":1909},[92],[15],[1418,1390],{"trials":1911,"activeCount":101},[],{"intervention":1913,"totalTrials":234,"cells":1914},"3HP",{"EARLY_PHASE1":1915,"PHASE1":1917,"PHASE2":1919,"PHASE3":1921,"PHASE4":1923,"NA":1934},{"trials":1916,"activeCount":101},[],{"trials":1918,"activeCount":101},[],{"trials":1920,"activeCount":101},[],{"trials":1922,"activeCount":101},[],{"trials":1924,"activeCount":101},[1925],{"nctId":1926,"briefTitle":1927,"status":109,"phases":1928,"primaryCompletion":1929,"completion":1929,"start":1930,"enrollment":1931,"conditions":1932,"interventions":1933},"NCT02689089","Taima TB: 3HP Study",[92],"2019-08-15","2016-11-28",182,[606],[1913],{"trials":1935,"activeCount":101},[],{"intervention":1937,"totalTrials":234,"cells":1938},"Dose dense AC-P",{"EARLY_PHASE1":1939,"PHASE1":1941,"PHASE2":1943,"PHASE3":1945,"PHASE4":1947,"NA":1960},{"trials":1940,"activeCount":101},[],{"trials":1942,"activeCount":101},[],{"trials":1944,"activeCount":101},[],{"trials":1946,"activeCount":101},[],{"trials":1948,"activeCount":101},[1949],{"nctId":1950,"briefTitle":1951,"status":1952,"phases":1953,"primaryCompletion":1954,"completion":1954,"start":1955,"enrollment":164,"conditions":1956,"interventions":1957},"NCT02688803","Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant\u002FAdjuvant Setting (REaCT-TNBC)","TERMINATED",[92],"2017-10","2016-08-30",[15],[1937,1958,1959],"Dose dense AC","FEC-D",{"trials":1961,"activeCount":101},[],{"intervention":1958,"totalTrials":234,"cells":1963},{"EARLY_PHASE1":1964,"PHASE1":1966,"PHASE2":1968,"PHASE3":1970,"PHASE4":1972,"NA":1978},{"trials":1965,"activeCount":101},[],{"trials":1967,"activeCount":101},[],{"trials":1969,"activeCount":101},[],{"trials":1971,"activeCount":101},[],{"trials":1973,"activeCount":101},[1974],{"nctId":1950,"briefTitle":1951,"status":1952,"phases":1975,"primaryCompletion":1954,"completion":1954,"start":1955,"enrollment":164,"conditions":1976,"interventions":1977},[92],[15],[1937,1958,1959],{"trials":1979,"activeCount":101},[],{"intervention":1959,"totalTrials":234,"cells":1981},{"EARLY_PHASE1":1982,"PHASE1":1984,"PHASE2":1986,"PHASE3":1988,"PHASE4":1990,"NA":1996},{"trials":1983,"activeCount":101},[],{"trials":1985,"activeCount":101},[],{"trials":1987,"activeCount":101},[],{"trials":1989,"activeCount":101},[],{"trials":1991,"activeCount":101},[1992],{"nctId":1950,"briefTitle":1951,"status":1952,"phases":1993,"primaryCompletion":1954,"completion":1954,"start":1955,"enrollment":164,"conditions":1994,"interventions":1995},[92],[15],[1937,1958,1959],{"trials":1997,"activeCount":101},[],{"intervention":1999,"totalTrials":234,"cells":2000},"Immunoglobulin replacement therapy",{"EARLY_PHASE1":2001,"PHASE1":2003,"PHASE2":2005,"PHASE3":2007,"PHASE4":2009,"NA":2020},{"trials":2002,"activeCount":101},[],{"trials":2004,"activeCount":101},[],{"trials":2006,"activeCount":101},[],{"trials":2008,"activeCount":101},[],{"trials":2010,"activeCount":101},[2011],{"nctId":2012,"briefTitle":2013,"status":548,"phases":2014,"primaryCompletion":2015,"completion":203,"start":2016,"enrollment":540,"conditions":2017,"interventions":2019},"NCT05612607","Switched Memory B-cells as a Marker for Humoral Immune System Recovery in Patients With Secondary Antibody Deficiency Due to Hematological Malignancies",[92],"2023-10-10","2022-11-10",[2018],"Secondary Antibody Deficiency",[1999],{"trials":2021,"activeCount":101},[],{"intervention":2023,"totalTrials":234,"cells":2024},"Dexamethasone, Ondansetron, Aprepitant",{"EARLY_PHASE1":2025,"PHASE1":2027,"PHASE2":2029,"PHASE3":2031,"PHASE4":2033,"NA":2045},{"trials":2026,"activeCount":101},[],{"trials":2028,"activeCount":101},[],{"trials":2030,"activeCount":101},[],{"trials":2032,"activeCount":101},[],{"trials":2034,"activeCount":101},[2035],{"nctId":2036,"briefTitle":2037,"status":548,"phases":2038,"primaryCompletion":2039,"completion":1238,"start":2040,"enrollment":2041,"conditions":2042,"interventions":2044},"NCT01913990","Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients.",[92],"2017-08","2011-09",323,[2043],"Emesis",[2023],{"trials":2046,"activeCount":101},[],{"intervention":2048,"totalTrials":234,"cells":2049},"Dexamethasone tapering dose",{"EARLY_PHASE1":2050,"PHASE1":2052,"PHASE2":2054,"PHASE3":2056,"PHASE4":2058,"NA":2071},{"trials":2051,"activeCount":101},[],{"trials":2053,"activeCount":101},[],{"trials":2055,"activeCount":101},[],{"trials":2057,"activeCount":101},[],{"trials":2059,"activeCount":101},[2060],{"nctId":2061,"briefTitle":2062,"status":109,"phases":2063,"primaryCompletion":2064,"completion":2064,"start":2065,"enrollment":2066,"conditions":2067,"interventions":2069},"NCT03348696","Comparing Tapering Low Dose Dexamethasone to Other Standard of Care Therapies for TAPS in Breast Cancer Patients",[92],"2019-04-02","2018-02-28",124,[342,2068],"Pain Syndrome",[2048,2070],"Dexamethasone physician choice",{"trials":2072,"activeCount":101},[],{"intervention":2070,"totalTrials":234,"cells":2074},{"EARLY_PHASE1":2075,"PHASE1":2077,"PHASE2":2079,"PHASE3":2081,"PHASE4":2083,"NA":2089},{"trials":2076,"activeCount":101},[],{"trials":2078,"activeCount":101},[],{"trials":2080,"activeCount":101},[],{"trials":2082,"activeCount":101},[],{"trials":2084,"activeCount":101},[2085],{"nctId":2061,"briefTitle":2062,"status":109,"phases":2086,"primaryCompletion":2064,"completion":2064,"start":2065,"enrollment":2066,"conditions":2087,"interventions":2088},[92],[342,2068],[2048,2070],{"trials":2090,"activeCount":101},[],{"intervention":2092,"totalTrials":234,"cells":2093},"Dexamethasone",{"EARLY_PHASE1":2094,"PHASE1":2096,"PHASE2":2098,"PHASE3":2100,"PHASE4":2102,"NA":2112},{"trials":2095,"activeCount":101},[],{"trials":2097,"activeCount":101},[],{"trials":2099,"activeCount":101},[],{"trials":2101,"activeCount":101},[],{"trials":2103,"activeCount":101},[2104],{"nctId":2105,"briefTitle":2106,"status":109,"phases":2107,"primaryCompletion":2108,"completion":491,"start":2109,"enrollment":1066,"conditions":2110,"interventions":2111},"NCT02815319","Schedules of Dexamethasone in Patients Incorrectly Taking Dexamethasone Premedication (REaCT-dexamethasone)",[92],"2018-10-30","2017-01",[18],[2092],{"trials":2113,"activeCount":101},[],{"intervention":1356,"totalTrials":234,"cells":2115},{"EARLY_PHASE1":2116,"PHASE1":2118,"PHASE2":2120,"PHASE3":2122,"PHASE4":2124,"NA":2130},{"trials":2117,"activeCount":101},[],{"trials":2119,"activeCount":101},[],{"trials":2121,"activeCount":101},[],{"trials":2123,"activeCount":101},[],{"trials":2125,"activeCount":101},[2126],{"nctId":1347,"briefTitle":1348,"status":109,"phases":2127,"primaryCompletion":1350,"completion":1351,"start":1352,"enrollment":1353,"conditions":2128,"interventions":2129},[92],[342],[1325,1356],{"trials":2131,"activeCount":101},[],{"intervention":2133,"totalTrials":234,"cells":2134},"unfractionated heparin",{"EARLY_PHASE1":2135,"PHASE1":2137,"PHASE2":2139,"PHASE3":2141,"PHASE4":2143,"NA":2154},{"trials":2136,"activeCount":101},[],{"trials":2138,"activeCount":101},[],{"trials":2140,"activeCount":101},[],{"trials":2142,"activeCount":101},[],{"trials":2144,"activeCount":101},[2145],{"nctId":2146,"briefTitle":2147,"status":109,"phases":2148,"primaryCompletion":1709,"completion":2149,"start":2150,"enrollment":196,"conditions":2151,"interventions":2153},"NCT00253851","Does Thinning the Blood During Surgery Prevent Blood Clots Following Total Knee Replacement Surgery",[92],"2011-06","2003-07",[2152,24],"DVT",[2133],{"trials":2155,"activeCount":101},[],{"intervention":2157,"totalTrials":234,"cells":2158},"Suprascapular and median nerve blocks",{"EARLY_PHASE1":2159,"PHASE1":2161,"PHASE2":2163,"PHASE3":2165,"PHASE4":2167,"NA":2178},{"trials":2160,"activeCount":101},[],{"trials":2162,"activeCount":101},[],{"trials":2164,"activeCount":101},[],{"trials":2166,"activeCount":101},[],{"trials":2168,"activeCount":101},[2169],{"nctId":2170,"briefTitle":2171,"status":109,"phases":2172,"primaryCompletion":2173,"completion":2173,"start":2174,"enrollment":97,"conditions":2175,"interventions":2177},"NCT03291197","Tolerability of Suprascapular and Median Nerve Blocks for the Treatment of Shoulder-hand Syndrome",[92],"2018-10-14","2017-10-15",[2176,1022],"Shoulder Hand Syndrome",[2157],{"trials":2179,"activeCount":101},[],{"intervention":1444,"totalTrials":234,"cells":2181},{"EARLY_PHASE1":2182,"PHASE1":2184,"PHASE2":2186,"PHASE3":2188,"PHASE4":2190,"NA":2196},{"trials":2183,"activeCount":101},[],{"trials":2185,"activeCount":101},[],{"trials":2187,"activeCount":101},[],{"trials":2189,"activeCount":101},[],{"trials":2191,"activeCount":101},[2192],{"nctId":1435,"briefTitle":1436,"status":109,"phases":2193,"primaryCompletion":1438,"completion":1386,"start":1439,"enrollment":1440,"conditions":2194,"interventions":2195},[92],[15,644,1442],[1422,1444,1445],{"trials":2197,"activeCount":101},[],{"intervention":1166,"totalTrials":234,"cells":2199},{"EARLY_PHASE1":2200,"PHASE1":2202,"PHASE2":2204,"PHASE3":2206,"PHASE4":2208,"NA":2214},{"trials":2201,"activeCount":101},[],{"trials":2203,"activeCount":101},[],{"trials":2205,"activeCount":101},[],{"trials":2207,"activeCount":101},[],{"trials":2209,"activeCount":101},[2210],{"nctId":1155,"briefTitle":1156,"status":548,"phases":2211,"primaryCompletion":1158,"completion":1158,"start":1159,"enrollment":1160,"conditions":2212,"interventions":2213},[92],[1162,1163],[1025,1165,1166],{"trials":2215,"activeCount":101},[],{"intervention":622,"totalTrials":234,"cells":2217},{"EARLY_PHASE1":2218,"PHASE1":2220,"PHASE2":2222,"PHASE3":2224,"PHASE4":2226,"NA":2232},{"trials":2219,"activeCount":101},[],{"trials":2221,"activeCount":101},[],{"trials":2223,"activeCount":101},[],{"trials":2225,"activeCount":101},[],{"trials":2227,"activeCount":101},[2228],{"nctId":612,"briefTitle":613,"status":601,"phases":2229,"primaryCompletion":615,"completion":615,"start":616,"enrollment":101,"conditions":2230,"interventions":2231},[92],[618,619,620],[622,560],{"trials":2233,"activeCount":101},[],{"intervention":1455,"totalTrials":234,"cells":2235},{"EARLY_PHASE1":2236,"PHASE1":2238,"PHASE2":2240,"PHASE3":2242,"PHASE4":2244,"NA":2250},{"trials":2237,"activeCount":101},[],{"trials":2239,"activeCount":101},[],{"trials":2241,"activeCount":101},[],{"trials":2243,"activeCount":101},[],{"trials":2245,"activeCount":101},[2246],{"nctId":1447,"briefTitle":1448,"status":109,"phases":2247,"primaryCompletion":1450,"completion":1450,"start":1451,"enrollment":1452,"conditions":2248,"interventions":2249},[92],[15],[1422,1455],{"trials":2251,"activeCount":101},[],{"intervention":2253,"totalTrials":164,"cells":2254},"Frozen Plasma",{"EARLY_PHASE1":2255,"PHASE1":2257,"PHASE2":2259,"PHASE3":2271,"PHASE4":2281,"NA":2283},{"trials":2256,"activeCount":101},[],{"trials":2258,"activeCount":101},[],{"trials":2260,"activeCount":101},[2261],{"nctId":2262,"briefTitle":2263,"status":109,"phases":2264,"primaryCompletion":2265,"completion":2265,"start":2266,"enrollment":2267,"conditions":2268,"interventions":2270},"NCT00302965","Effectiveness of Plasma Transfusions in Critical Care Patients",[89,90],"2006-12","2005-04",70,[2269],"Coagulation",[2253],{"trials":2272,"activeCount":101},[2273],{"nctId":2274,"briefTitle":2275,"status":548,"phases":2276,"primaryCompletion":2277,"completion":550,"start":1450,"enrollment":1257,"conditions":2278,"interventions":2279},"NCT02561026","Transfusion of Plasma Prior to Invasive Procedures Pilot Trial (TOPPIT)",[91],"2018-08",[1739],[2280],"Frozen plasma",{"trials":2282,"activeCount":101},[],{"trials":2284,"activeCount":101},[],{"intervention":2286,"totalTrials":164,"cells":2287},"Pregabalin",{"EARLY_PHASE1":2288,"PHASE1":2290,"PHASE2":2292,"PHASE3":2304,"PHASE4":2315,"NA":2317},{"trials":2289,"activeCount":101},[],{"trials":2291,"activeCount":101},[],{"trials":2293,"activeCount":101},[2294],{"nctId":2295,"briefTitle":2296,"status":548,"phases":2297,"primaryCompletion":2298,"completion":2298,"start":2299,"enrollment":868,"conditions":2300,"interventions":2302},"NCT02482818","Efficacy of Pregabalin on Chronic Cough",[89,90],"2021-12-31","2015-09",[2301],"Cough",[2286,2303],"Control-Placebo",{"trials":2305,"activeCount":101},[2306],{"nctId":2307,"briefTitle":2308,"status":109,"phases":2309,"primaryCompletion":2040,"completion":575,"start":2310,"enrollment":290,"conditions":2311,"interventions":2314},"NCT00819988","Pregabalin in the Prevention of Postoperative Delirium and Pain",[91],"2009-05",[2312,2313],"Delirium","Pain",[2286],{"trials":2316,"activeCount":101},[],{"trials":2318,"activeCount":101},[],{"intervention":2320,"totalTrials":164,"cells":2321},"dalteparin sodium",{"EARLY_PHASE1":2322,"PHASE1":2324,"PHASE2":2326,"PHASE3":2328,"PHASE4":2352,"NA":2354},{"trials":2323,"activeCount":101},[],{"trials":2325,"activeCount":101},[],{"trials":2327,"activeCount":101},[],{"trials":2329,"activeCount":101},[2330,2342],{"nctId":2331,"briefTitle":2332,"status":109,"phases":2333,"primaryCompletion":2334,"completion":2334,"start":2335,"enrollment":2336,"conditions":2337,"interventions":2341},"NCT00967382","TIPPS: Thrombophilia in Pregnancy Prophylaxis Study",[91],"2014-03","2000-07",292,[2338,2339,2340],"Pregnancy","Thrombophilia","Pregnancy Complications",[2320],{"nctId":2343,"briefTitle":2344,"status":109,"phases":2345,"primaryCompletion":1240,"completion":1240,"start":2346,"enrollment":2347,"conditions":2348,"interventions":2350},"NCT01274637","PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot",[91],"2011-03",62,[21,2349],"Postpartum",[2351],"Dalteparin Sodium",{"trials":2353,"activeCount":101},[],{"trials":2355,"activeCount":101},[],{"intervention":2357,"totalTrials":164,"cells":2358},"Olanzapine",{"EARLY_PHASE1":2359,"PHASE1":2361,"PHASE2":2363,"PHASE3":2374,"PHASE4":2386,"NA":2388},{"trials":2360,"activeCount":101},[],{"trials":2362,"activeCount":101},[],{"trials":2364,"activeCount":101},[2365],{"nctId":2366,"briefTitle":2367,"status":109,"phases":2368,"primaryCompletion":1336,"completion":2369,"start":2370,"enrollment":16,"conditions":2371,"interventions":2373},"NCT00260962","Olanzapine in the Treatment of Patients With Anorexia Nervosa",[90],"2006-09","2000-09",[2372],"Anorexia Nervosa",[2357],{"trials":2375,"activeCount":101},[2376],{"nctId":2377,"briefTitle":2378,"status":109,"phases":2379,"primaryCompletion":2380,"completion":2380,"start":2381,"enrollment":2382,"conditions":2383,"interventions":2384},"NCT02861859","Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD Study",[91],"2019-12-23","2016-12",221,[15],[2357,2385],"Olanzapine Placebo",{"trials":2387,"activeCount":101},[],{"trials":2389,"activeCount":101},[],{"intervention":1246,"totalTrials":234,"cells":2391},{"EARLY_PHASE1":2392,"PHASE1":2394,"PHASE2":2396,"PHASE3":2398,"PHASE4":2404,"NA":2406},{"trials":2393,"activeCount":101},[],{"trials":2395,"activeCount":101},[],{"trials":2397,"activeCount":101},[],{"trials":2399,"activeCount":101},[2400],{"nctId":1235,"briefTitle":1236,"status":548,"phases":2401,"primaryCompletion":1238,"completion":1239,"start":1240,"enrollment":1241,"conditions":2402,"interventions":2403},[91],[1243,1244],[1224,1246],{"trials":2405,"activeCount":101},[],{"trials":2407,"activeCount":101},[],{"intervention":2409,"totalTrials":234,"cells":2410},"Kaletra",{"EARLY_PHASE1":2411,"PHASE1":2413,"PHASE2":2415,"PHASE3":2417,"PHASE4":2428,"NA":2430},{"trials":2412,"activeCount":101},[],{"trials":2414,"activeCount":101},[],{"trials":2416,"activeCount":101},[],{"trials":2418,"activeCount":101},[2419],{"nctId":2420,"briefTitle":2421,"status":109,"phases":2422,"primaryCompletion":2346,"completion":2423,"start":2424,"enrollment":2425,"conditions":2426,"interventions":2427},"NCT00508222","Kaletra Monotherapy in HIV\u002FHCV Co-infected Subjects",[91],"2011-04","2007-06",22,[607],[2409],{"trials":2429,"activeCount":101},[],{"trials":2431,"activeCount":101},[],{"intervention":2433,"totalTrials":234,"cells":2434},"Fluviral",{"EARLY_PHASE1":2435,"PHASE1":2437,"PHASE2":2439,"PHASE3":2441,"PHASE4":2454,"NA":2456},{"trials":2436,"activeCount":101},[],{"trials":2438,"activeCount":101},[],{"trials":2440,"activeCount":101},[],{"trials":2442,"activeCount":101},[2443],{"nctId":2444,"briefTitle":2445,"status":109,"phases":2446,"primaryCompletion":2447,"completion":2448,"start":2449,"enrollment":2450,"conditions":2451,"interventions":2453},"NCT00764998","Influenza Vaccine in HIV",[91],"2009-04","2009-08","2008-10",285,[2452,1243],"Influenza",[2433],{"trials":2455,"activeCount":101},[],{"trials":2457,"activeCount":101},[],{"intervention":2459,"totalTrials":234,"cells":2460},"Ribavirin",{"EARLY_PHASE1":2461,"PHASE1":2463,"PHASE2":2465,"PHASE3":2467,"PHASE4":2480,"NA":2482},{"trials":2462,"activeCount":101},[],{"trials":2464,"activeCount":101},[],{"trials":2466,"activeCount":101},[],{"trials":2468,"activeCount":101},[2469],{"nctId":2470,"briefTitle":2471,"status":548,"phases":2472,"primaryCompletion":2473,"completion":2474,"start":2475,"enrollment":1685,"conditions":2476,"interventions":2478},"NCT03759782","Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity",[91],"2022-01-31","2022-09-30","2019-01-10",[2477],"Hepatitis B, Chronic",[2459,2479],"Tenofovir",{"trials":2481,"activeCount":101},[],{"trials":2483,"activeCount":101},[],{"intervention":2479,"totalTrials":234,"cells":2485},{"EARLY_PHASE1":2486,"PHASE1":2488,"PHASE2":2490,"PHASE3":2492,"PHASE4":2498,"NA":2500},{"trials":2487,"activeCount":101},[],{"trials":2489,"activeCount":101},[],{"trials":2491,"activeCount":101},[],{"trials":2493,"activeCount":101},[2494],{"nctId":2470,"briefTitle":2471,"status":548,"phases":2495,"primaryCompletion":2473,"completion":2474,"start":2475,"enrollment":1685,"conditions":2496,"interventions":2497},[91],[2477],[2459,2479],{"trials":2499,"activeCount":101},[],{"trials":2501,"activeCount":101},[],{"intervention":2503,"totalTrials":234,"cells":2504},"E\u002FC\u002FF\u002FTAF;",{"EARLY_PHASE1":2505,"PHASE1":2507,"PHASE2":2509,"PHASE3":2511,"PHASE4":2526,"NA":2528},{"trials":2506,"activeCount":101},[],{"trials":2508,"activeCount":101},[],{"trials":2510,"activeCount":101},[],{"trials":2512,"activeCount":101},[2513],{"nctId":2514,"briefTitle":2515,"status":109,"phases":2516,"primaryCompletion":2517,"completion":2518,"start":2519,"enrollment":2520,"conditions":2521,"interventions":2524},"NCT02660905","HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection",[91],"2018-01","2018-06","2016-04",25,[2522,2523],"Human Immunodeficiency Virus","Hepatitis C, Chronic",[2503,2525],"Ledipasvir-Sofosbuvir",{"trials":2527,"activeCount":101},[],{"trials":2529,"activeCount":101},[],{"intervention":2525,"totalTrials":234,"cells":2531},{"EARLY_PHASE1":2532,"PHASE1":2534,"PHASE2":2536,"PHASE3":2538,"PHASE4":2544,"NA":2546},{"trials":2533,"activeCount":101},[],{"trials":2535,"activeCount":101},[],{"trials":2537,"activeCount":101},[],{"trials":2539,"activeCount":101},[2540],{"nctId":2514,"briefTitle":2515,"status":109,"phases":2541,"primaryCompletion":2517,"completion":2518,"start":2519,"enrollment":2520,"conditions":2542,"interventions":2543},[91],[2522,2523],[2503,2525],{"trials":2545,"activeCount":101},[],{"trials":2547,"activeCount":101},[],{"intervention":2549,"totalTrials":234,"cells":2550},"Oxygen",{"EARLY_PHASE1":2551,"PHASE1":2553,"PHASE2":2555,"PHASE3":2557,"PHASE4":2569,"NA":2571},{"trials":2552,"activeCount":101},[],{"trials":2554,"activeCount":101},[],{"trials":2556,"activeCount":101},[],{"trials":2558,"activeCount":101},[2559],{"nctId":2560,"briefTitle":2561,"status":548,"phases":2562,"primaryCompletion":2563,"completion":2563,"start":2564,"enrollment":2565,"conditions":2566,"interventions":2568},"NCT04500626","Hyperbaric Versus Normobaric Oxygen Therapy for COVID-19 Patients",[90,91],"2022-08","2021-04-15",234,[2567],"Covid19",[2549],{"trials":2570,"activeCount":101},[],{"trials":2572,"activeCount":101},[],{"intervention":581,"totalTrials":234,"cells":2574},{"EARLY_PHASE1":2575,"PHASE1":2577,"PHASE2":2579,"PHASE3":2581,"PHASE4":2587,"NA":2589},{"trials":2576,"activeCount":101},[],{"trials":2578,"activeCount":101},[],{"trials":2580,"activeCount":101},[],{"trials":2582,"activeCount":101},[2583],{"nctId":571,"briefTitle":572,"status":109,"phases":2584,"primaryCompletion":574,"completion":575,"start":576,"enrollment":577,"conditions":2585,"interventions":2586},[90,91],[579],[560,581,582],{"trials":2588,"activeCount":101},[],{"trials":2590,"activeCount":101},[],{"intervention":2592,"totalTrials":234,"cells":2593},"Heme Iron Polypeptide",{"EARLY_PHASE1":2594,"PHASE1":2596,"PHASE2":2598,"PHASE3":2600,"PHASE4":2614,"NA":2616},{"trials":2595,"activeCount":101},[],{"trials":2597,"activeCount":101},[],{"trials":2599,"activeCount":101},[],{"trials":2601,"activeCount":101},[2602],{"nctId":2603,"briefTitle":2604,"status":109,"phases":2605,"primaryCompletion":2606,"completion":2606,"start":2607,"enrollment":2608,"conditions":2609,"interventions":2612},"NCT00318812","Heme Iron Polypeptide for Iron Deficiency Anemia in Chronic Renal Failure",[90,91],"2011-12","2007-05",55,[2610,2611],"Anemia","Renal Failure",[2592,2613],"Iron sucrose",{"trials":2615,"activeCount":101},[],{"trials":2617,"activeCount":101},[],{"intervention":2613,"totalTrials":234,"cells":2619},{"EARLY_PHASE1":2620,"PHASE1":2622,"PHASE2":2624,"PHASE3":2626,"PHASE4":2632,"NA":2634},{"trials":2621,"activeCount":101},[],{"trials":2623,"activeCount":101},[],{"trials":2625,"activeCount":101},[],{"trials":2627,"activeCount":101},[2628],{"nctId":2603,"briefTitle":2604,"status":109,"phases":2629,"primaryCompletion":2606,"completion":2606,"start":2607,"enrollment":2608,"conditions":2630,"interventions":2631},[90,91],[2610,2611],[2592,2613],{"trials":2633,"activeCount":101},[],{"trials":2635,"activeCount":101},[],{"intervention":2637,"totalTrials":234,"cells":2638},"Folic Acid 4 mg",{"EARLY_PHASE1":2639,"PHASE1":2641,"PHASE2":2643,"PHASE3":2645,"PHASE4":2656,"NA":2658},{"trials":2640,"activeCount":101},[],{"trials":2642,"activeCount":101},[],{"trials":2644,"activeCount":101},[],{"trials":2646,"activeCount":101},[2647],{"nctId":2648,"briefTitle":2649,"status":109,"phases":2650,"primaryCompletion":2651,"completion":1376,"start":2423,"enrollment":2652,"conditions":2653,"interventions":2655},"NCT01355159","High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention",[91],"2016-07",2464,[2340,2654],"Preeclampsia",[2637],{"trials":2657,"activeCount":101},[],{"trials":2659,"activeCount":101},[],{"intervention":2661,"totalTrials":234,"cells":2662},"Theophylline",{"EARLY_PHASE1":2663,"PHASE1":2665,"PHASE2":2667,"PHASE3":2669,"PHASE4":2680,"NA":2682},{"trials":2664,"activeCount":101},[],{"trials":2666,"activeCount":101},[],{"trials":2668,"activeCount":101},[],{"trials":2670,"activeCount":101},[2671],{"nctId":2672,"briefTitle":2673,"status":109,"phases":2674,"primaryCompletion":2675,"completion":2675,"start":2676,"enrollment":1685,"conditions":2677,"interventions":2679},"NCT00299858","Theophylline in Chronic Obstructive Pulmonary Disease",[90,91],"2010-05","2006-10",[2678],"COPD",[2661],{"trials":2681,"activeCount":101},[],{"trials":2683,"activeCount":101},[],{"intervention":2685,"totalTrials":234,"cells":2686},"Propranolol Hydrochloride",{"EARLY_PHASE1":2687,"PHASE1":2689,"PHASE2":2691,"PHASE3":2693,"PHASE4":2706,"NA":2708},{"trials":2688,"activeCount":101},[],{"trials":2690,"activeCount":101},[],{"trials":2692,"activeCount":101},[],{"trials":2694,"activeCount":101},[2695],{"nctId":2696,"briefTitle":2697,"status":109,"phases":2698,"primaryCompletion":2699,"completion":2699,"start":2700,"enrollment":128,"conditions":2701,"interventions":2705},"NCT04467086","Propranolol as an Anxiolytic to Reduce the Use of Sedatives From Critically-ill Adults Receiving Mechanical Ventilation",[91],"2022-11-30","2021-01-08",[2702,2703,412,2704],"Mechanical Ventilation","Sedation","COVID",[2685],{"trials":2707,"activeCount":101},[],{"trials":2709,"activeCount":101},[],{"intervention":2711,"totalTrials":234,"cells":2712},"Methadone",{"EARLY_PHASE1":2713,"PHASE1":2715,"PHASE2":2717,"PHASE3":2719,"PHASE4":2732,"NA":2734},{"trials":2714,"activeCount":101},[],{"trials":2716,"activeCount":101},[],{"trials":2718,"activeCount":101},[],{"trials":2720,"activeCount":101},[2721],{"nctId":2722,"briefTitle":2723,"status":601,"phases":2724,"primaryCompletion":2725,"completion":2726,"start":1159,"enrollment":101,"conditions":2727,"interventions":2730},"NCT05325164","Methadone for 'Adenocarcinopathic' Pain Treatment",[91],"2023-08","2023-09",[2728,2729],"Cancer Pain","Adenocarcinoma",[2711,2731],"Morphine",{"trials":2733,"activeCount":101},[],{"trials":2735,"activeCount":101},[],{"intervention":2731,"totalTrials":234,"cells":2737},{"EARLY_PHASE1":2738,"PHASE1":2740,"PHASE2":2742,"PHASE3":2744,"PHASE4":2750,"NA":2752},{"trials":2739,"activeCount":101},[],{"trials":2741,"activeCount":101},[],{"trials":2743,"activeCount":101},[],{"trials":2745,"activeCount":101},[2746],{"nctId":2722,"briefTitle":2723,"status":601,"phases":2747,"primaryCompletion":2725,"completion":2726,"start":1159,"enrollment":101,"conditions":2748,"interventions":2749},[91],[2728,2729],[2711,2731],{"trials":2751,"activeCount":101},[],{"trials":2753,"activeCount":101},[],{"intervention":2755,"totalTrials":234,"cells":2756},"Fragmin",{"EARLY_PHASE1":2757,"PHASE1":2759,"PHASE2":2761,"PHASE3":2763,"PHASE4":2776,"NA":2778},{"trials":2758,"activeCount":101},[],{"trials":2760,"activeCount":101},[],{"trials":2762,"activeCount":101},[],{"trials":2764,"activeCount":101},[2765],{"nctId":2766,"briefTitle":2767,"status":109,"phases":2768,"primaryCompletion":576,"completion":576,"start":2769,"enrollment":2770,"conditions":2771,"interventions":2774},"NCT00260988","A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery",[90,91],"2003-10",29,[2772,2773],"Thromboembolism","Hemodialysis",[2755,2775],"Innohep",{"trials":2777,"activeCount":101},[],{"trials":2779,"activeCount":101},[],{"intervention":2775,"totalTrials":234,"cells":2781},{"EARLY_PHASE1":2782,"PHASE1":2784,"PHASE2":2786,"PHASE3":2788,"PHASE4":2794,"NA":2796},{"trials":2783,"activeCount":101},[],{"trials":2785,"activeCount":101},[],{"trials":2787,"activeCount":101},[],{"trials":2789,"activeCount":101},[2790],{"nctId":2766,"briefTitle":2767,"status":109,"phases":2791,"primaryCompletion":576,"completion":576,"start":2769,"enrollment":2770,"conditions":2792,"interventions":2793},[90,91],[2772,2773],[2755,2775],{"trials":2795,"activeCount":101},[],{"trials":2797,"activeCount":101},[],{"intervention":2799,"totalTrials":234,"cells":2800},"Potassium Citrate",{"EARLY_PHASE1":2801,"PHASE1":2803,"PHASE2":2805,"PHASE3":2807,"PHASE4":2818,"NA":2820},{"trials":2802,"activeCount":101},[],{"trials":2804,"activeCount":101},[],{"trials":2806,"activeCount":101},[],{"trials":2808,"activeCount":101},[2809],{"nctId":2810,"briefTitle":2811,"status":109,"phases":2812,"primaryCompletion":2813,"completion":2813,"start":2814,"enrollment":2815,"conditions":2816,"interventions":2817},"NCT03809884","Dietary Counseling or Potassium Supplement to Increase Potassium Intake in Patients With High Blood Pressure",[91],"2024-07-22","2019-12-01",7,[30],[2799],{"trials":2819,"activeCount":101},[],{"trials":2821,"activeCount":101},[],{"intervention":2823,"totalTrials":234,"cells":2824},"Leuprolide acetate",{"EARLY_PHASE1":2825,"PHASE1":2827,"PHASE2":2829,"PHASE3":2831,"PHASE4":2843,"NA":2845},{"trials":2826,"activeCount":101},[],{"trials":2828,"activeCount":101},[],{"trials":2830,"activeCount":101},[],{"trials":2832,"activeCount":101},[2833],{"nctId":2834,"briefTitle":2835,"status":109,"phases":2836,"primaryCompletion":2837,"completion":2838,"start":2839,"enrollment":196,"conditions":2840,"interventions":2842},"NCT00380406","PROtecting Ovaries and Fertility During Chemotherapy - The PROOF Trial",[91],"2010-01","2010-04","2007-01",[2841,18],"Fertility Preservation",[2823],{"trials":2844,"activeCount":101},[],{"trials":2846,"activeCount":101},[],{"intervention":2385,"totalTrials":234,"cells":2848},{"EARLY_PHASE1":2849,"PHASE1":2851,"PHASE2":2853,"PHASE3":2855,"PHASE4":2861,"NA":2863},{"trials":2850,"activeCount":101},[],{"trials":2852,"activeCount":101},[],{"trials":2854,"activeCount":101},[],{"trials":2856,"activeCount":101},[2857],{"nctId":2377,"briefTitle":2378,"status":109,"phases":2858,"primaryCompletion":2380,"completion":2380,"start":2381,"enrollment":2382,"conditions":2859,"interventions":2860},[91],[15],[2357,2385],{"trials":2862,"activeCount":101},[],{"trials":2864,"activeCount":101},[],{"intervention":2866,"totalTrials":234,"cells":2867},"Curosurf-Group1",{"EARLY_PHASE1":2868,"PHASE1":2870,"PHASE2":2872,"PHASE3":2874,"PHASE4":2884,"NA":2886},{"trials":2869,"activeCount":101},[],{"trials":2871,"activeCount":101},[],{"trials":2873,"activeCount":101},[],{"trials":2875,"activeCount":101},[2876],{"nctId":2877,"briefTitle":2878,"status":109,"phases":2879,"primaryCompletion":1439,"completion":1439,"start":1735,"enrollment":8,"conditions":2880,"interventions":2882},"NCT01709409","A Multi-center Trial to Determine if Curosurf® Reduces the Duration of Mechanical Ventilation in Very Preterm Infants",[91],[2881],"Respiratory Distress Syndrome",[2866,2883],"BLES-group 2",{"trials":2885,"activeCount":101},[],{"trials":2887,"activeCount":101},[],{"intervention":2883,"totalTrials":234,"cells":2889},{"EARLY_PHASE1":2890,"PHASE1":2892,"PHASE2":2894,"PHASE3":2896,"PHASE4":2902,"NA":2904},{"trials":2891,"activeCount":101},[],{"trials":2893,"activeCount":101},[],{"trials":2895,"activeCount":101},[],{"trials":2897,"activeCount":101},[2898],{"nctId":2877,"briefTitle":2878,"status":109,"phases":2899,"primaryCompletion":1439,"completion":1439,"start":1735,"enrollment":8,"conditions":2900,"interventions":2901},[91],[2881],[2866,2883],{"trials":2903,"activeCount":101},[],{"trials":2905,"activeCount":101},[],{"intervention":2907,"totalTrials":234,"cells":2908},"Oxytocin",{"EARLY_PHASE1":2909,"PHASE1":2911,"PHASE2":2913,"PHASE3":2915,"PHASE4":2928,"NA":2930},{"trials":2910,"activeCount":101},[],{"trials":2912,"activeCount":101},[],{"trials":2914,"activeCount":101},[],{"trials":2916,"activeCount":101},[2917],{"nctId":2918,"briefTitle":2919,"status":1952,"phases":2920,"primaryCompletion":2921,"completion":2922,"start":2923,"enrollment":2924,"conditions":2925,"interventions":2927},"NCT01397630","Accelerated Titration of Oxytocin for Nulliparous Patients With Labour Dystocia: ACTION Pilot Study",[91],"2013-10","2013-11","2012-04",79,[2926],"Labour Dystocia",[2907],{"trials":2929,"activeCount":101},[],{"trials":2931,"activeCount":101},[],{"intervention":2933,"totalTrials":164,"cells":2934},"Doxycycline",{"EARLY_PHASE1":2935,"PHASE1":2937,"PHASE2":2939,"PHASE3":2956,"PHASE4":2958,"NA":2960},{"trials":2936,"activeCount":101},[],{"trials":2938,"activeCount":101},[],{"trials":2940,"activeCount":101},[2941,2948],{"nctId":2942,"briefTitle":2943,"status":548,"phases":2944,"primaryCompletion":2298,"completion":2298,"start":2149,"enrollment":868,"conditions":2945,"interventions":2947},"NCT01411202","Effectiveness of Doxycycline for Treating Pleural Effusions Related to Cancer in an Outpatient Population",[90],[2946],"Malignant Pleural Effusion",[2933],{"nctId":2949,"briefTitle":2950,"status":109,"phases":2951,"primaryCompletion":125,"completion":125,"start":2952,"enrollment":2953,"conditions":2954,"interventions":2955},"NCT01847976","Combining Doxycycline With Bone-Targeted Therapy in Patients With Metastatic Breast Cancer",[90],"2013-08",73,[2313],[2933],{"trials":2957,"activeCount":101},[],{"trials":2959,"activeCount":101},[],{"trials":2961,"activeCount":101},[],{"intervention":2963,"totalTrials":164,"cells":2964},"Aspirin 81 mg",{"EARLY_PHASE1":2965,"PHASE1":2978,"PHASE2":2980,"PHASE3":2999,"PHASE4":3001,"NA":3003},{"trials":2966,"activeCount":101},[2967],{"nctId":2968,"briefTitle":2969,"status":1952,"phases":2970,"primaryCompletion":2971,"completion":2971,"start":2972,"enrollment":234,"conditions":2973,"interventions":2976},"NCT03100123","AntiPhospholipid Syndrome Low-molecular-weight Heparin Pregnancy Loss Evaluation: The Pilot Study",[88],"2019-10-07","2017-11-06",[2974,2975],"Antiphospholipid Syndrome in Pregnancy","Pregnancy Loss",[2963,2977],"Low-molecular-weight heparin",{"trials":2979,"activeCount":101},[],{"trials":2981,"activeCount":101},[2982],{"nctId":2983,"briefTitle":2984,"status":109,"phases":2985,"primaryCompletion":2986,"completion":2987,"start":2988,"enrollment":2989,"conditions":2990,"interventions":2997},"NCT04243122","Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients",[90],"2023-10-31","2024-05-03","2021-02-17",44,[2991,2992,2993,2994,2995,2996],"Myeloproliferative Neoplasm (MPN)","Essential Thrombocythemia (ET)","JAK2 Mutation","Polycythemia Vera (PV)","Primary Myelofibrosis","Venous Thromboembolism (VTE)",[2998,2963],"Apixaban 2.5 MG Oral Tablet [ELIQUIS]",{"trials":3000,"activeCount":101},[],{"trials":3002,"activeCount":101},[],{"trials":3004,"activeCount":101},[],{"intervention":3006,"totalTrials":164,"cells":3007},"Intravenous immunoglobulin",{"EARLY_PHASE1":3008,"PHASE1":3010,"PHASE2":3012,"PHASE3":3032,"PHASE4":3034,"NA":3036},{"trials":3009,"activeCount":101},[],{"trials":3011,"activeCount":101},[],{"trials":3013,"activeCount":101},[3014,3024],{"nctId":3015,"briefTitle":3016,"status":109,"phases":3017,"primaryCompletion":3018,"completion":3018,"start":1376,"enrollment":3019,"conditions":3020,"interventions":3022},"NCT02690038","Ig PRx in AECOPD: Pilot Study",[90],"2019-11-20",48,[3021],"Chronic Obstructive Pulmonary Disease",[3006,3023],"Normal Saline",{"nctId":3025,"briefTitle":3026,"status":109,"phases":3027,"primaryCompletion":3018,"completion":3018,"start":3028,"enrollment":2425,"conditions":3029,"interventions":3031},"NCT03018652","Feasibility and Safety of Immunoglobulin (Ig) Treatment in COPD Outpatients With Frequent Exacerbations: Pilot Study 1",[90],"2018-03-11",[3030],"Chronic Obstructive Pulmonary Disease (COPD)",[3006,3023],{"trials":3033,"activeCount":101},[],{"trials":3035,"activeCount":101},[],{"trials":3037,"activeCount":101},[],{"intervention":3039,"totalTrials":234,"cells":3040},"Durvalumab",{"EARLY_PHASE1":3041,"PHASE1":3043,"PHASE2":3045,"PHASE3":3057,"PHASE4":3059,"NA":3061},{"trials":3042,"activeCount":101},[],{"trials":3044,"activeCount":101},[],{"trials":3046,"activeCount":101},[3047],{"nctId":3048,"briefTitle":3049,"status":548,"phases":3050,"primaryCompletion":3051,"completion":3052,"start":3053,"enrollment":3054,"conditions":3055,"interventions":3056},"NCT04543110","Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC",[90],"2023-10","2024-11","2021-01-29",16,[521],[3039],{"trials":3058,"activeCount":101},[],{"trials":3060,"activeCount":101},[],{"trials":3062,"activeCount":101},[],{"intervention":3064,"totalTrials":234,"cells":3065},"Exemestane",{"EARLY_PHASE1":3066,"PHASE1":3068,"PHASE2":3070,"PHASE3":3082,"PHASE4":3084,"NA":3086},{"trials":3067,"activeCount":101},[],{"trials":3069,"activeCount":101},[],{"trials":3071,"activeCount":101},[3072],{"nctId":3073,"briefTitle":3074,"status":109,"phases":3075,"primaryCompletion":3076,"completion":3077,"start":3078,"enrollment":196,"conditions":3079,"interventions":3081},"NCT00261027","Aromasin (Exemestane) in Patients With Recurrent or Refractory Stage II - IV Epithelial Ovarian Cancer",[90],"2007-07","2007-09","2003-01",[3080],"Ovarian Cancer",[3064],{"trials":3083,"activeCount":101},[],{"trials":3085,"activeCount":101},[],{"trials":3087,"activeCount":101},[],{"intervention":3089,"totalTrials":234,"cells":3090},"Degarelix",{"EARLY_PHASE1":3091,"PHASE1":3093,"PHASE2":3095,"PHASE3":3104,"PHASE4":3106,"NA":3108},{"trials":3092,"activeCount":101},[],{"trials":3094,"activeCount":101},[],{"trials":3096,"activeCount":101},[3097],{"nctId":3098,"briefTitle":3099,"status":1952,"phases":3100,"primaryCompletion":575,"completion":3101,"start":1709,"enrollment":97,"conditions":3102,"interventions":3103},"NCT01545882","A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer",[90],"2013-07",[930],[3089],{"trials":3105,"activeCount":101},[],{"trials":3107,"activeCount":101},[],{"trials":3109,"activeCount":101},[],{"intervention":3111,"totalTrials":234,"cells":3112},"Chloroquine",{"EARLY_PHASE1":3113,"PHASE1":3115,"PHASE2":3117,"PHASE3":3127,"PHASE4":3129,"NA":3131},{"trials":3114,"activeCount":101},[],{"trials":3116,"activeCount":101},[],{"trials":3118,"activeCount":101},[3119],{"nctId":3120,"briefTitle":3121,"status":548,"phases":3122,"primaryCompletion":1255,"completion":3123,"start":1684,"enrollment":1066,"conditions":3124,"interventions":3126},"NCT02333890","A Phase 2 Randomized, Double-blind Trial Evaluating the Effects of Chloroquine in Breast Cancer",[90],"2018-03",[15,3125],"Invasive Breast Cancer",[3111],{"trials":3128,"activeCount":101},[],{"trials":3130,"activeCount":101},[],{"trials":3132,"activeCount":101},[],{"intervention":2998,"totalTrials":234,"cells":3134},{"EARLY_PHASE1":3135,"PHASE1":3137,"PHASE2":3139,"PHASE3":3145,"PHASE4":3147,"NA":3149},{"trials":3136,"activeCount":101},[],{"trials":3138,"activeCount":101},[],{"trials":3140,"activeCount":101},[3141],{"nctId":2983,"briefTitle":2984,"status":109,"phases":3142,"primaryCompletion":2986,"completion":2987,"start":2988,"enrollment":2989,"conditions":3143,"interventions":3144},[90],[2991,2992,2993,2994,2995,2996],[2998,2963],{"trials":3146,"activeCount":101},[],{"trials":3148,"activeCount":101},[],{"trials":3150,"activeCount":101},[],{"intervention":3152,"totalTrials":234,"cells":3153},"INT230-6",{"EARLY_PHASE1":3154,"PHASE1":3156,"PHASE2":3158,"PHASE3":3170,"PHASE4":3172,"NA":3174},{"trials":3155,"activeCount":101},[],{"trials":3157,"activeCount":101},[],{"trials":3159,"activeCount":101},[3160],{"nctId":3161,"briefTitle":3162,"status":548,"phases":3163,"primaryCompletion":3164,"completion":3165,"start":3166,"enrollment":3167,"conditions":3168,"interventions":3169},"NCT04781725","INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer",[90],"2022-03-01","2023-03-01","2021-03-25",90,[15],[3152],{"trials":3171,"activeCount":101},[],{"trials":3173,"activeCount":101},[],{"trials":3175,"activeCount":101},[],{"intervention":3177,"totalTrials":234,"cells":3178},"Mesenchymal Stem Cells",{"EARLY_PHASE1":3179,"PHASE1":3181,"PHASE2":3183,"PHASE3":3194,"PHASE4":3196,"NA":3198},{"trials":3180,"activeCount":101},[],{"trials":3182,"activeCount":101},[],{"trials":3184,"activeCount":101},[3185],{"nctId":3186,"briefTitle":3187,"status":109,"phases":3188,"primaryCompletion":538,"completion":538,"start":3189,"enrollment":3190,"conditions":3191,"interventions":3193},"NCT02239393","Safety and Efficacy of Intravenous Autologous Mesenchymal Stem Cells for MS: a Phase 2 Proof of Concept Study",[90],"2015-06",31,[3192],"Multiple Sclerosis",[3177],{"trials":3195,"activeCount":101},[],{"trials":3197,"activeCount":101},[],{"trials":3199,"activeCount":101},[],{"intervention":3201,"totalTrials":234,"cells":3202},"UC-MSCs",{"EARLY_PHASE1":3203,"PHASE1":3205,"PHASE2":3207,"PHASE3":3218,"PHASE4":3220,"NA":3222},{"trials":3204,"activeCount":101},[],{"trials":3206,"activeCount":101},[],{"trials":3208,"activeCount":101},[3209],{"nctId":3210,"briefTitle":3211,"status":109,"phases":3212,"primaryCompletion":3213,"completion":3213,"start":3214,"enrollment":2425,"conditions":3215,"interventions":3217},"NCT04865107","Cellular Immuno-Therapy for COVID-19 ARDS Randomized Clinical Trial",[90],"2022-04-01","2021-04-27",[2567,3216],"Acute Respiratory Distress Syndrome",[3201],{"trials":3219,"activeCount":101},[],{"trials":3221,"activeCount":101},[],{"trials":3223,"activeCount":101},[],{"intervention":3225,"totalTrials":234,"cells":3226},"5% albumin",{"EARLY_PHASE1":3227,"PHASE1":3229,"PHASE2":3231,"PHASE3":3243,"PHASE4":3245,"NA":3247},{"trials":3228,"activeCount":101},[],{"trials":3230,"activeCount":101},[],{"trials":3232,"activeCount":101},[3233],{"nctId":3234,"briefTitle":3235,"status":109,"phases":3236,"primaryCompletion":3237,"completion":3238,"start":3239,"enrollment":1090,"conditions":3240,"interventions":3242},"NCT00819416","Fluid Resuscitation in Early Septic Shock",[90],"2009-10","2010-02","2009-02",[898,899,3241],"Severe Sepsis",[3225,3023],{"trials":3244,"activeCount":101},[],{"trials":3246,"activeCount":101},[],{"trials":3248,"activeCount":101},[],{"intervention":3250,"totalTrials":234,"cells":3251},"Remune and ALVAC",{"EARLY_PHASE1":3252,"PHASE1":3254,"PHASE2":3256,"PHASE3":3267,"PHASE4":3269,"NA":3271},{"trials":3253,"activeCount":101},[],{"trials":3255,"activeCount":101},[],{"trials":3257,"activeCount":101},[3258],{"nctId":3259,"briefTitle":3260,"status":109,"phases":3261,"primaryCompletion":3262,"completion":3263,"start":3264,"enrollment":316,"conditions":3265,"interventions":3266},"NCT00212888","Combination Vaccination Before HIV Treatment Interruption",[89,90],"2010-07","2010-11","2004-04",[607],[3250],{"trials":3268,"activeCount":101},[],{"trials":3270,"activeCount":101},[],{"trials":3272,"activeCount":101},[],{"intervention":3274,"totalTrials":234,"cells":3275},"irinotecan, capecitabine, oxaliplatin (IXO) and bevacizumab",{"EARLY_PHASE1":3276,"PHASE1":3278,"PHASE2":3280,"PHASE3":3290,"PHASE4":3292,"NA":3294},{"trials":3277,"activeCount":101},[],{"trials":3279,"activeCount":101},[],{"trials":3281,"activeCount":101},[3282],{"nctId":3283,"briefTitle":3284,"status":601,"phases":3285,"primaryCompletion":3286,"completion":3286,"start":2346,"enrollment":101,"conditions":3287,"interventions":3289},"NCT01293942","IXO+A in mCRC With Liver-only Metastases",[90],"2012-02",[3288],"Metastatic Colorectal Cancer",[3274],{"trials":3291,"activeCount":101},[],{"trials":3293,"activeCount":101},[],{"trials":3295,"activeCount":101},[],{"intervention":3297,"totalTrials":234,"cells":3298},"Oxygen Gas for Inhalation",{"EARLY_PHASE1":3299,"PHASE1":3301,"PHASE2":3303,"PHASE3":3315,"PHASE4":3317,"NA":3319},{"trials":3300,"activeCount":101},[],{"trials":3302,"activeCount":101},[],{"trials":3304,"activeCount":101},[3305],{"nctId":3306,"briefTitle":3307,"status":548,"phases":3308,"primaryCompletion":3309,"completion":3310,"start":3311,"enrollment":868,"conditions":3312,"interventions":3314},"NCT06109961","Hyperbaric Oxygen Therapy for Perianal Fistulizing Crohn's Disease Not Responsive or Intolerant to Conventional Care: HYPNOTIC Pilot Study",[89,90],"2026-01","2026-03","2024-01",[3313],"Inflammatory Bowel Disease (IBD)",[3297],{"trials":3316,"activeCount":101},[],{"trials":3318,"activeCount":101},[],{"trials":3320,"activeCount":101},[],{"intervention":3322,"totalTrials":234,"cells":3323},"Dalteparin",{"EARLY_PHASE1":3324,"PHASE1":3326,"PHASE2":3328,"PHASE3":3340,"PHASE4":3342,"NA":3344},{"trials":3325,"activeCount":101},[],{"trials":3327,"activeCount":101},[],{"trials":3329,"activeCount":101},[3330],{"nctId":3331,"briefTitle":3332,"status":1952,"phases":3333,"primaryCompletion":3334,"completion":3334,"start":3335,"enrollment":3336,"conditions":3337,"interventions":3339},"NCT03297359","WAVe Study - Weight Adjusted Dalteparin for Patients Over 90 kg With Acute Cancer Associated Venous Thromboembolism",[90],"2023-11-30","2018-03-21",92,[18,21,3338],"Obesity",[3322],{"trials":3341,"activeCount":101},[],{"trials":3343,"activeCount":101},[],{"trials":3345,"activeCount":101},[],{"intervention":3347,"totalTrials":234,"cells":3348},"Anastrozole",{"EARLY_PHASE1":3349,"PHASE1":3351,"PHASE2":3353,"PHASE3":3362,"PHASE4":3364,"NA":3366},{"trials":3350,"activeCount":101},[],{"trials":3352,"activeCount":101},[],{"trials":3354,"activeCount":101},[3355],{"nctId":3356,"briefTitle":3357,"status":109,"phases":3358,"primaryCompletion":1414,"completion":1414,"start":3359,"enrollment":19,"conditions":3360,"interventions":3361},"NCT01972984","Feasibility Study of Presurgical Hormone Therapy (Anastrozole) in Breast Cancer Patients",[90],"2012-10",[15],[3347],{"trials":3363,"activeCount":101},[],{"trials":3365,"activeCount":101},[],{"trials":3367,"activeCount":101},[],{"intervention":3369,"totalTrials":234,"cells":3370},"Metformin",{"EARLY_PHASE1":3371,"PHASE1":3373,"PHASE2":3375,"PHASE3":3387,"PHASE4":3389,"NA":3391},{"trials":3372,"activeCount":101},[],{"trials":3374,"activeCount":101},[],{"trials":3376,"activeCount":101},[3377],{"nctId":3378,"briefTitle":3379,"status":601,"phases":3380,"primaryCompletion":3381,"completion":3382,"start":1450,"enrollment":101,"conditions":3383,"interventions":3385},"NCT02306070","Improving Fibrosis Outcomes With Metformin",[90],"2017-09-30","2018-04-03",[3384,1687],"HIV Infection",[3369,3386],"No metformin treatment",{"trials":3388,"activeCount":101},[],{"trials":3390,"activeCount":101},[],{"trials":3392,"activeCount":101},[],{"intervention":3386,"totalTrials":234,"cells":3394},{"EARLY_PHASE1":3395,"PHASE1":3397,"PHASE2":3399,"PHASE3":3405,"PHASE4":3407,"NA":3409},{"trials":3396,"activeCount":101},[],{"trials":3398,"activeCount":101},[],{"trials":3400,"activeCount":101},[3401],{"nctId":3378,"briefTitle":3379,"status":601,"phases":3402,"primaryCompletion":3381,"completion":3382,"start":1450,"enrollment":101,"conditions":3403,"interventions":3404},[90],[3384,1687],[3369,3386],{"trials":3406,"activeCount":101},[],{"trials":3408,"activeCount":101},[],{"trials":3410,"activeCount":101},[],{"intervention":3412,"totalTrials":234,"cells":3413},"IXO regimen + bevacizumab",{"EARLY_PHASE1":3414,"PHASE1":3416,"PHASE2":3418,"PHASE3":3429,"PHASE4":3431,"NA":3433},{"trials":3415,"activeCount":101},[],{"trials":3417,"activeCount":101},[],{"trials":3419,"activeCount":101},[3420],{"nctId":3421,"briefTitle":3422,"status":1952,"phases":3423,"primaryCompletion":3286,"completion":3424,"start":3425,"enrollment":3426,"conditions":3427,"interventions":3428},"NCT00819754","A Phase I\u002FII Study of IXO With Bevacizumab in Patients With Metastatic Colorectal Cancer",[89,90],"2012-05","2003-11",23,[3288],[3412],{"trials":3430,"activeCount":101},[],{"trials":3432,"activeCount":101},[],{"trials":3434,"activeCount":101},[],{"intervention":3436,"totalTrials":234,"cells":3437},"Mesenchymal Stromal Cells",{"EARLY_PHASE1":3438,"PHASE1":3440,"PHASE2":3442,"PHASE3":3452,"PHASE4":3454,"NA":3456},{"trials":3439,"activeCount":101},[],{"trials":3441,"activeCount":101},[],{"trials":3443,"activeCount":101},[3444],{"nctId":3445,"briefTitle":3446,"status":109,"phases":3447,"primaryCompletion":3448,"completion":3448,"start":3449,"enrollment":25,"conditions":3450,"interventions":3451},"NCT04400032","Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome",[89,90],"2021-04-22","2020-05-15",[3216,2567],[3436],{"trials":3453,"activeCount":101},[],{"trials":3455,"activeCount":101},[],{"trials":3457,"activeCount":101},[],{"intervention":3459,"totalTrials":234,"cells":3460},"Vedolizumab",{"EARLY_PHASE1":3461,"PHASE1":3463,"PHASE2":3465,"PHASE3":3477,"PHASE4":3479,"NA":3481},{"trials":3462,"activeCount":101},[],{"trials":3464,"activeCount":101},[],{"trials":3466,"activeCount":101},[3467],{"nctId":3468,"briefTitle":3469,"status":548,"phases":3470,"primaryCompletion":3471,"completion":3471,"start":3472,"enrollment":3473,"conditions":3474,"interventions":3476},"NCT03147859","Vedolizumab Treatment in Antiretroviral Drug Treated Chronic HIV Infection",[90],"2023-12-31","2017-11-01",10,[3475],"HIV-infection\u002FAIDS",[3459],{"trials":3478,"activeCount":101},[],{"trials":3480,"activeCount":101},[],{"trials":3482,"activeCount":101},[],{"intervention":3484,"totalTrials":234,"cells":3485},"25% Albumin fluid",{"EARLY_PHASE1":3486,"PHASE1":3488,"PHASE2":3490,"PHASE3":3500,"PHASE4":3502,"NA":3504},{"trials":3487,"activeCount":101},[],{"trials":3489,"activeCount":101},[],{"trials":3491,"activeCount":101},[3492],{"nctId":3493,"briefTitle":3494,"status":109,"phases":3495,"primaryCompletion":3496,"completion":3496,"start":3497,"enrollment":1066,"conditions":3498,"interventions":3499},"NCT03665311","Saline Versus Albumin Fluid for Extracorporeal Removal With Slow Low Efficiency Dialysis Feasibility Study",[90],"2020-01-15","2019-03-25",[410,409,411],[3484],{"trials":3501,"activeCount":101},[],{"trials":3503,"activeCount":101},[],{"trials":3505,"activeCount":101},[],{"intervention":3507,"totalTrials":234,"cells":3508},"Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells",{"EARLY_PHASE1":3509,"PHASE1":3511,"PHASE2":3513,"PHASE3":3525,"PHASE4":3527,"NA":3529},{"trials":3510,"activeCount":101},[],{"trials":3512,"activeCount":101},[],{"trials":3514,"activeCount":101},[3515],{"nctId":3516,"briefTitle":3517,"status":548,"phases":3518,"primaryCompletion":3519,"completion":3520,"start":3123,"enrollment":3521,"conditions":3522,"interventions":3524},"NCT03369275","Cellular Immunotherapy for Septic Shock",[90],"2020-02","2020-10",114,[898,899,900,901,3523,902,903],"Infection",[3507],{"trials":3526,"activeCount":101},[],{"trials":3528,"activeCount":101},[],{"trials":3530,"activeCount":101},[],{"intervention":3532,"totalTrials":234,"cells":3533},"Rosuvastatin",{"EARLY_PHASE1":3534,"PHASE1":3536,"PHASE2":3538,"PHASE3":3550,"PHASE4":3552,"NA":3554},{"trials":3535,"activeCount":101},[],{"trials":3537,"activeCount":101},[],{"trials":3539,"activeCount":101},[3540],{"nctId":3541,"briefTitle":3542,"status":548,"phases":3543,"primaryCompletion":3544,"completion":3545,"start":3546,"enrollment":3547,"conditions":3548,"interventions":3549},"NCT02679664","StAtins for Venous Event Reduction in Patients With Venous Thromboembolism Pilot Study",[90],"2020-01-13","2020-07","2016-11",312,[21],[3532],{"trials":3551,"activeCount":101},[],{"trials":3553,"activeCount":101},[],{"trials":3555,"activeCount":101},[],{"intervention":3557,"totalTrials":234,"cells":3558},"IXO regimen",{"EARLY_PHASE1":3559,"PHASE1":3561,"PHASE2":3563,"PHASE3":3573,"PHASE4":3575,"NA":3577},{"trials":3560,"activeCount":101},[],{"trials":3562,"activeCount":101},[],{"trials":3564,"activeCount":101},[3565],{"nctId":3566,"briefTitle":3567,"status":548,"phases":3568,"primaryCompletion":1734,"completion":1238,"start":3569,"enrollment":25,"conditions":3570,"interventions":3572},"NCT01237665","IXO (Irinotecan, Xeloda, Oxaliplatin) in Rectal Cancer",[90],"2010-09",[3571],"Rectal Cancer",[3557],{"trials":3574,"activeCount":101},[],{"trials":3576,"activeCount":101},[],{"trials":3578,"activeCount":101},[],{"intervention":3580,"totalTrials":234,"cells":3581},"Vitamin D3",{"EARLY_PHASE1":3582,"PHASE1":3584,"PHASE2":3586,"PHASE3":3595,"PHASE4":3597,"NA":3599},{"trials":3583,"activeCount":101},[],{"trials":3585,"activeCount":101},[],{"trials":3587,"activeCount":101},[3588],{"nctId":3589,"briefTitle":3590,"status":109,"phases":3591,"primaryCompletion":2299,"completion":2299,"start":2921,"enrollment":3592,"conditions":3593,"interventions":3594},"NCT01948128","Effects of Vitamin D in Patients With Breast Cancer",[90],83,[15],[3580],{"trials":3596,"activeCount":101},[],{"trials":3598,"activeCount":101},[],{"trials":3600,"activeCount":101},[],{"intervention":3602,"totalTrials":234,"cells":3603},"GSK3326595",{"EARLY_PHASE1":3604,"PHASE1":3606,"PHASE2":3608,"PHASE3":3618,"PHASE4":3620,"NA":3622},{"trials":3605,"activeCount":101},[],{"trials":3607,"activeCount":101},[],{"trials":3609,"activeCount":101},[3610],{"nctId":3611,"briefTitle":3612,"status":109,"phases":3613,"primaryCompletion":3614,"completion":3614,"start":3615,"enrollment":868,"conditions":3616,"interventions":3617},"NCT04676516","A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer",[90],"2022-08-15","2021-06-08",[15],[3602],{"trials":3619,"activeCount":101},[],{"trials":3621,"activeCount":101},[],{"trials":3623,"activeCount":101},[],{"intervention":3625,"totalTrials":234,"cells":3626},"Resveratrol",{"EARLY_PHASE1":3627,"PHASE1":3629,"PHASE2":3631,"PHASE3":3641,"PHASE4":3643,"NA":3645},{"trials":3628,"activeCount":101},[],{"trials":3630,"activeCount":101},[],{"trials":3632,"activeCount":101},[3633],{"nctId":3634,"briefTitle":3635,"status":109,"phases":3636,"primaryCompletion":574,"completion":574,"start":3239,"enrollment":3637,"conditions":3638,"interventions":3640},"NCT01615445","Resveratrol Supplementation on Exercise in Healthy Sedentary Adults",[90],13,[3639],"Sedentary Lifestyle",[3625],{"trials":3642,"activeCount":101},[],{"trials":3644,"activeCount":101},[],{"trials":3646,"activeCount":101},[],{"intervention":3648,"totalTrials":234,"cells":3649},"rivaroxaban plus aspirin",{"EARLY_PHASE1":3650,"PHASE1":3652,"PHASE2":3654,"PHASE3":3666,"PHASE4":3668,"NA":3670},{"trials":3651,"activeCount":101},[],{"trials":3653,"activeCount":101},[],{"trials":3655,"activeCount":101},[3656],{"nctId":3657,"briefTitle":3658,"status":109,"phases":3659,"primaryCompletion":3660,"completion":3661,"start":1505,"enrollment":19,"conditions":3662,"interventions":3664},"NCT02260622","Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb Ischemia",[90],"2017-06","2019-03",[3663],"Critical Limb Ischemia",[3648,3665],"clopidogrel plus aspirin",{"trials":3667,"activeCount":101},[],{"trials":3669,"activeCount":101},[],{"trials":3671,"activeCount":101},[],{"intervention":3665,"totalTrials":234,"cells":3673},{"EARLY_PHASE1":3674,"PHASE1":3676,"PHASE2":3678,"PHASE3":3684,"PHASE4":3686,"NA":3688},{"trials":3675,"activeCount":101},[],{"trials":3677,"activeCount":101},[],{"trials":3679,"activeCount":101},[3680],{"nctId":3657,"briefTitle":3658,"status":109,"phases":3681,"primaryCompletion":3660,"completion":3661,"start":1505,"enrollment":19,"conditions":3682,"interventions":3683},[90],[3663],[3648,3665],{"trials":3685,"activeCount":101},[],{"trials":3687,"activeCount":101},[],{"trials":3689,"activeCount":101},[],{"intervention":2303,"totalTrials":234,"cells":3691},{"EARLY_PHASE1":3692,"PHASE1":3694,"PHASE2":3696,"PHASE3":3702,"PHASE4":3704,"NA":3706},{"trials":3693,"activeCount":101},[],{"trials":3695,"activeCount":101},[],{"trials":3697,"activeCount":101},[3698],{"nctId":2295,"briefTitle":2296,"status":548,"phases":3699,"primaryCompletion":2298,"completion":2298,"start":2299,"enrollment":868,"conditions":3700,"interventions":3701},[89,90],[2301],[2286,2303],{"trials":3703,"activeCount":101},[],{"trials":3705,"activeCount":101},[],{"trials":3707,"activeCount":101},[],{"intervention":3709,"totalTrials":234,"cells":3710},"Glycopyrrolate",{"EARLY_PHASE1":3711,"PHASE1":3713,"PHASE2":3715,"PHASE3":3728,"PHASE4":3730,"NA":3732},{"trials":3712,"activeCount":101},[],{"trials":3714,"activeCount":101},[],{"trials":3716,"activeCount":101},[3717],{"nctId":3718,"briefTitle":3719,"status":548,"phases":3720,"primaryCompletion":3721,"completion":3722,"start":2651,"enrollment":3723,"conditions":3724,"interventions":3727},"NCT02382198","Study of Glycopyrrolate for Moderate-to-severe Sialorrhea in Parkinson's Disease",[90],"2018-10","2018-12",28,[3725,3726],"Sialorrhea","Parkinson's Disease",[3709],{"trials":3729,"activeCount":101},[],{"trials":3731,"activeCount":101},[],{"trials":3733,"activeCount":101},[],{"intervention":3735,"totalTrials":234,"cells":3736},"Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab",{"EARLY_PHASE1":3737,"PHASE1":3739,"PHASE2":3741,"PHASE3":3750,"PHASE4":3752,"NA":3754},{"trials":3738,"activeCount":101},[],{"trials":3740,"activeCount":101},[],{"trials":3742,"activeCount":101},[3743],{"nctId":3744,"briefTitle":3745,"status":548,"phases":3746,"primaryCompletion":204,"completion":204,"start":3747,"enrollment":19,"conditions":3748,"interventions":3749},"NCT05967884","PD-1 +\u002F- IL-4 Inhibition in ER+ Breast Cancer",[90],"2023-08-04",[15],[3735],{"trials":3751,"activeCount":101},[],{"trials":3753,"activeCount":101},[],{"trials":3755,"activeCount":101},[],{"intervention":3757,"totalTrials":234,"cells":3758},"Seribantumab",{"EARLY_PHASE1":3759,"PHASE1":3761,"PHASE2":3763,"PHASE3":3774,"PHASE4":3776,"NA":3778},{"trials":3760,"activeCount":101},[],{"trials":3762,"activeCount":101},[],{"trials":3764,"activeCount":101},[3765],{"nctId":3766,"briefTitle":3767,"status":109,"phases":3768,"primaryCompletion":3769,"completion":3769,"start":3770,"enrollment":234,"conditions":3771,"interventions":3773},"NCT04790695","Single Patient Protocol for an NRG1 Fusion Positive Metastatic Pancreatic Cancer Patient Using Seribantumab",[90],"2021-12-22","2021-03-29",[3772],"Metastatic Pancreatic Cancer",[3757],{"trials":3775,"activeCount":101},[],{"trials":3777,"activeCount":101},[],{"trials":3779,"activeCount":101},[],{"intervention":3781,"totalTrials":234,"cells":3782},"Tamoxifen",{"EARLY_PHASE1":3783,"PHASE1":3785,"PHASE2":3787,"PHASE3":3796,"PHASE4":3798,"NA":3800},{"trials":3784,"activeCount":101},[],{"trials":3786,"activeCount":101},[],{"trials":3788,"activeCount":101},[3789],{"nctId":3790,"briefTitle":3791,"status":548,"phases":3792,"primaryCompletion":2277,"completion":2277,"start":2039,"enrollment":3793,"conditions":3794,"interventions":3795},"NCT03211572","The EMPOwER Study Evaluating Multiparameter Gene Testing as a Predictor of Short Term Endocrine Therapy Response in Hormone Receptor Positive Breast Cancers",[90],82,[15],[3781],{"trials":3797,"activeCount":101},[],{"trials":3799,"activeCount":101},[],{"trials":3801,"activeCount":101},[],{"intervention":3803,"totalTrials":234,"cells":3804},"Cialis",{"EARLY_PHASE1":3805,"PHASE1":3807,"PHASE2":3820,"PHASE3":3822,"PHASE4":3824,"NA":3826},{"trials":3806,"activeCount":101},[],{"trials":3808,"activeCount":101},[3809],{"nctId":3810,"briefTitle":3811,"status":109,"phases":3812,"primaryCompletion":3813,"completion":3814,"start":3815,"enrollment":3723,"conditions":3816,"interventions":3818},"NCT02998736","Trial of Perioperative Tadalafil and Influenza Vaccination in Cancer Patients Undergoing Major Surgical Resection of a Primary Abdominal Malignancy",[89],"2022-09-01","2022-10-01","2017-11-21",[3817],"Abdominal Cancer",[3803,3819],"Influenza vaccine",{"trials":3821,"activeCount":101},[],{"trials":3823,"activeCount":101},[],{"trials":3825,"activeCount":101},[],{"trials":3827,"activeCount":101},[],{"intervention":3819,"totalTrials":234,"cells":3829},{"EARLY_PHASE1":3830,"PHASE1":3832,"PHASE2":3838,"PHASE3":3840,"PHASE4":3842,"NA":3844},{"trials":3831,"activeCount":101},[],{"trials":3833,"activeCount":101},[3834],{"nctId":3810,"briefTitle":3811,"status":109,"phases":3835,"primaryCompletion":3813,"completion":3814,"start":3815,"enrollment":3723,"conditions":3836,"interventions":3837},[89],[3817],[3803,3819],{"trials":3839,"activeCount":101},[],{"trials":3841,"activeCount":101},[],{"trials":3843,"activeCount":101},[],{"trials":3845,"activeCount":101},[],{"intervention":3847,"totalTrials":234,"cells":3848},"Allogeneic mesenchymal stromal cells",{"EARLY_PHASE1":3849,"PHASE1":3851,"PHASE2":3860,"PHASE3":3862,"PHASE4":3864,"NA":3866},{"trials":3850,"activeCount":101},[],{"trials":3852,"activeCount":101},[3853],{"nctId":3854,"briefTitle":3855,"status":109,"phases":3856,"primaryCompletion":1504,"completion":2108,"start":3857,"enrollment":31,"conditions":3858,"interventions":3859},"NCT02421484","Cellular Immunotherapy for Septic Shock: A Phase I Trial",[89],"2015-05",[898],[3847],{"trials":3861,"activeCount":101},[],{"trials":3863,"activeCount":101},[],{"trials":3865,"activeCount":101},[],{"trials":3867,"activeCount":101},[],{"intervention":3869,"totalTrials":234,"cells":3870},"Acitretin",{"EARLY_PHASE1":3871,"PHASE1":3873,"PHASE2":3883,"PHASE3":3885,"PHASE4":3887,"NA":3889},{"trials":3872,"activeCount":101},[],{"trials":3874,"activeCount":101},[3875],{"nctId":3876,"briefTitle":3877,"status":601,"phases":3878,"primaryCompletion":3879,"completion":3879,"start":3880,"enrollment":101,"conditions":3881,"interventions":3882},"NCT03753867","RA Effect on Cell Surface Molecules in Vivo",[89],"2019-05-08","2019-01-07",[607],[3869],{"trials":3884,"activeCount":101},[],{"trials":3886,"activeCount":101},[],{"trials":3888,"activeCount":101},[],{"trials":3890,"activeCount":101},[],{"intervention":3892,"totalTrials":234,"cells":3893},"sorafenib + FOLFIRI",{"EARLY_PHASE1":3894,"PHASE1":3896,"PHASE2":3904,"PHASE3":3906,"PHASE4":3908,"NA":3910},{"trials":3895,"activeCount":101},[],{"trials":3897,"activeCount":101},[3898],{"nctId":3899,"briefTitle":3900,"status":109,"phases":3901,"primaryCompletion":1709,"completion":1734,"start":2449,"enrollment":3054,"conditions":3902,"interventions":3903},"NCT00780169","Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer",[89],[3288],[3892],{"trials":3905,"activeCount":101},[],{"trials":3907,"activeCount":101},[],{"trials":3909,"activeCount":101},[],{"trials":3911,"activeCount":101},[],{"intervention":3913,"totalTrials":234,"cells":3914},"Amlodipine",{"EARLY_PHASE1":3915,"PHASE1":3917,"PHASE2":3927,"PHASE3":3929,"PHASE4":3931,"NA":3933},{"trials":3916,"activeCount":101},[],{"trials":3918,"activeCount":101},[3919],{"nctId":3920,"briefTitle":3921,"status":601,"phases":3922,"primaryCompletion":3923,"start":3424,"enrollment":101,"conditions":3924,"interventions":3925},"NCT01549496","A Drug Interaction Study of Boceprevir in Combination With Amlodipine or Diltiazem in Healthy Volunteers",[89],"2012-09",[1687,30],[3913,3926],"Diltiazem",{"trials":3928,"activeCount":101},[],{"trials":3930,"activeCount":101},[],{"trials":3932,"activeCount":101},[],{"trials":3934,"activeCount":101},[],{"intervention":3926,"totalTrials":234,"cells":3936},{"EARLY_PHASE1":3937,"PHASE1":3939,"PHASE2":3945,"PHASE3":3947,"PHASE4":3949,"NA":3951},{"trials":3938,"activeCount":101},[],{"trials":3940,"activeCount":101},[3941],{"nctId":3920,"briefTitle":3921,"status":601,"phases":3942,"primaryCompletion":3923,"start":3424,"enrollment":101,"conditions":3943,"interventions":3944},[89],[1687,30],[3913,3926],{"trials":3946,"activeCount":101},[],{"trials":3948,"activeCount":101},[],{"trials":3950,"activeCount":101},[],{"trials":3952,"activeCount":101},[],{"intervention":3954,"totalTrials":234,"cells":3955},"Erlotinib + Rosuvastatin",{"EARLY_PHASE1":3956,"PHASE1":3958,"PHASE2":3970,"PHASE3":3972,"PHASE4":3974,"NA":3976},{"trials":3957,"activeCount":101},[],{"trials":3959,"activeCount":101},[3960],{"nctId":3961,"briefTitle":3962,"status":109,"phases":3963,"primaryCompletion":3964,"completion":3964,"start":3965,"enrollment":1685,"conditions":3966,"interventions":3969},"NCT00966472","Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC",[89],"2014-09","2009-03",[3967,3968],"Squamous Cell Carcinoma","Non-Small Cell Lung Cancer",[3954],{"trials":3971,"activeCount":101},[],{"trials":3973,"activeCount":101},[],{"trials":3975,"activeCount":101},[],{"trials":3977,"activeCount":101},[],{"intervention":3979,"totalTrials":234,"cells":3980},"Rifabutin",{"EARLY_PHASE1":3981,"PHASE1":3983,"PHASE2":3996,"PHASE3":3998,"PHASE4":4000,"NA":4002},{"trials":3982,"activeCount":101},[],{"trials":3984,"activeCount":101},[3985],{"nctId":3986,"briefTitle":3987,"status":109,"phases":3988,"primaryCompletion":3989,"completion":3990,"start":518,"enrollment":25,"conditions":3991,"interventions":3994},"NCT01894776","A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc",[89],"2013-12","2015-02",[3384,3992,3993],"HIV-1 Infection","Mycobacterium Avium Complex (MAC)",[3979,3995],"Maraviroc",{"trials":3997,"activeCount":101},[],{"trials":3999,"activeCount":101},[],{"trials":4001,"activeCount":101},[],{"trials":4003,"activeCount":101},[],{"intervention":3995,"totalTrials":234,"cells":4005},{"EARLY_PHASE1":4006,"PHASE1":4008,"PHASE2":4014,"PHASE3":4016,"PHASE4":4018,"NA":4020},{"trials":4007,"activeCount":101},[],{"trials":4009,"activeCount":101},[4010],{"nctId":3986,"briefTitle":3987,"status":109,"phases":4011,"primaryCompletion":3989,"completion":3990,"start":518,"enrollment":25,"conditions":4012,"interventions":4013},[89],[3384,3992,3993],[3979,3995],{"trials":4015,"activeCount":101},[],{"trials":4017,"activeCount":101},[],{"trials":4019,"activeCount":101},[],{"trials":4021,"activeCount":101},[],{"intervention":4023,"totalTrials":234,"cells":4024},"atazanavir 300mg boosted with ritonavir 50 mg",{"EARLY_PHASE1":4025,"PHASE1":4027,"PHASE2":4036,"PHASE3":4038,"PHASE4":4040,"NA":4042},{"trials":4026,"activeCount":101},[],{"trials":4028,"activeCount":101},[4029],{"nctId":4030,"briefTitle":4031,"status":109,"phases":4032,"primaryCompletion":4033,"completion":2299,"start":1240,"enrollment":28,"conditions":4034,"interventions":4035},"NCT02034838","Microboosting of Atazanavir 300 mg With 50 mg Versus 100mg Ritonavir Daily in HIV-infected Patients: a Pharmacokinetic Study",[89],"2014-11",[3384],[4023],{"trials":4037,"activeCount":101},[],{"trials":4039,"activeCount":101},[],{"trials":4041,"activeCount":101},[],{"trials":4043,"activeCount":101},[],{"intervention":2977,"totalTrials":234,"cells":4045},{"EARLY_PHASE1":4046,"PHASE1":4052,"PHASE2":4054,"PHASE3":4056,"PHASE4":4058,"NA":4060},{"trials":4047,"activeCount":101},[4048],{"nctId":2968,"briefTitle":2969,"status":1952,"phases":4049,"primaryCompletion":2971,"completion":2971,"start":2972,"enrollment":234,"conditions":4050,"interventions":4051},[88],[2974,2975],[2963,2977],{"trials":4053,"activeCount":101},[],{"trials":4055,"activeCount":101},[],{"trials":4057,"activeCount":101},[],{"trials":4059,"activeCount":101},[],{"trials":4061,"activeCount":101},[],{"intervention":3023,"totalTrials":4063,"cells":4064},6,{"EARLY_PHASE1":4065,"PHASE1":4067,"PHASE2":4069,"PHASE3":4083,"PHASE4":4094,"NA":4104},{"trials":4066,"activeCount":101},[],{"trials":4068,"activeCount":101},[],{"trials":4070,"activeCount":101},[4071,4075,4079],{"nctId":3234,"briefTitle":3235,"status":109,"phases":4072,"primaryCompletion":3237,"completion":3238,"start":3239,"enrollment":1090,"conditions":4073,"interventions":4074},[90],[898,899,3241],[3225,3023],{"nctId":3015,"briefTitle":3016,"status":109,"phases":4076,"primaryCompletion":3018,"completion":3018,"start":1376,"enrollment":3019,"conditions":4077,"interventions":4078},[90],[3021],[3006,3023],{"nctId":3025,"briefTitle":3026,"status":109,"phases":4080,"primaryCompletion":3018,"completion":3018,"start":3028,"enrollment":2425,"conditions":4081,"interventions":4082},[90],[3030],[3006,3023],{"trials":4084,"activeCount":101},[4085],{"nctId":4086,"briefTitle":4087,"status":109,"phases":4088,"primaryCompletion":4089,"completion":1684,"start":4090,"enrollment":481,"conditions":4091,"interventions":4093},"NCT02154763","The Use of Intraperitoneal Ropivacaine in Bariatric Bypass Surgery",[91],"2015-01","2014-07",[4092],"Bariatric Surgery Candidate",[1165,3023],{"trials":4095,"activeCount":101},[4096],{"nctId":4097,"briefTitle":4098,"status":548,"phases":4099,"primaryCompletion":3519,"completion":3519,"start":4100,"enrollment":693,"conditions":4101,"interventions":4102},"NCT03367728","The Use of Laparoscopic Transversus Abdominis Plane Block in Gastric Bypass Surgery (LapTAP)",[92],"2018-11-27",[4092],[1165,4103],"Normal saline",{"trials":4105,"activeCount":101},[4106],{"nctId":4107,"briefTitle":4108,"status":109,"phases":4109,"primaryCompletion":4110,"completion":4110,"start":4111,"enrollment":577,"conditions":4112,"interventions":4117},"NCT03038425","Does Continuous Adductor Canal Nerve Block Improve the Quality of Recovery for Outpatient Total Knee Arthroplasty Patients?",[93],"2020-04-01","2017-05-02",[4113,4114,4115,4116],"Arthroplasty, Replacement, Knee","Nerve Block","Anesthesia, Regional","Ambulatory Surgical Procedures",[3023,1165],{"intervention":1165,"totalTrials":502,"cells":4119},{"EARLY_PHASE1":4120,"PHASE1":4122,"PHASE2":4124,"PHASE3":4126,"PHASE4":4132,"NA":4142},{"trials":4121,"activeCount":101},[],{"trials":4123,"activeCount":101},[],{"trials":4125,"activeCount":101},[],{"trials":4127,"activeCount":101},[4128],{"nctId":4086,"briefTitle":4087,"status":109,"phases":4129,"primaryCompletion":4089,"completion":1684,"start":4090,"enrollment":481,"conditions":4130,"interventions":4131},[91],[4092],[1165,3023],{"trials":4133,"activeCount":101},[4134,4138],{"nctId":1155,"briefTitle":1156,"status":548,"phases":4135,"primaryCompletion":1158,"completion":1158,"start":1159,"enrollment":1160,"conditions":4136,"interventions":4137},[92],[1162,1163],[1025,1165,1166],{"nctId":4097,"briefTitle":4098,"status":548,"phases":4139,"primaryCompletion":3519,"completion":3519,"start":4100,"enrollment":693,"conditions":4140,"interventions":4141},[92],[4092],[1165,4103],{"trials":4143,"activeCount":101},[4144],{"nctId":4107,"briefTitle":4108,"status":109,"phases":4145,"primaryCompletion":4110,"completion":4110,"start":4111,"enrollment":577,"conditions":4146,"interventions":4147},[93],[4113,4114,4115,4116],[3023,1165],{"intervention":4149,"totalTrials":168,"cells":4150},"Tinzaparin",{"EARLY_PHASE1":4151,"PHASE1":4153,"PHASE2":4155,"PHASE3":4157,"PHASE4":4176,"NA":4178},{"trials":4152,"activeCount":101},[],{"trials":4154,"activeCount":101},[],{"trials":4156,"activeCount":101},[],{"trials":4158,"activeCount":101},[4159,4169],{"nctId":4160,"briefTitle":4161,"status":109,"phases":4162,"primaryCompletion":4163,"completion":4164,"start":2040,"enrollment":4165,"conditions":4166,"interventions":4168},"NCT01455831","Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer",[91],"2020-12-31","2021-02-01",616,[4167],"Adenocarcinoma of the Colon",[4149,4149],{"nctId":4170,"briefTitle":4171,"status":109,"phases":4172,"completion":2369,"start":4173,"enrollment":196,"conditions":4174,"interventions":4175},"NCT00225108","The STOP CLOT Pilot Study: Study of Low Molecular Weight Heparin in High Risk Cesarean Section",[90,91],"2002-07",[36],[4149],{"trials":4177,"activeCount":101},[],{"trials":4179,"activeCount":101},[4180],{"nctId":4181,"briefTitle":4182,"status":109,"phases":4183,"primaryCompletion":3569,"completion":3569,"start":603,"enrollment":4184,"conditions":4185,"interventions":4187},"NCT00967148","Thromboprophylaxis for Patients Undergoing Surgical Resection for Colon Cancer",[93],18,[36,4186,18],"Pulmonary Embolism",[4149],{"intervention":4189,"totalTrials":164,"cells":4190},"Atorvastatin",{"EARLY_PHASE1":4191,"PHASE1":4193,"PHASE2":4195,"PHASE3":4197,"PHASE4":4199,"NA":4201},{"trials":4192,"activeCount":101},[],{"trials":4194,"activeCount":101},[],{"trials":4196,"activeCount":101},[],{"trials":4198,"activeCount":101},[],{"trials":4200,"activeCount":101},[],{"trials":4202,"activeCount":101},[4203,4211],{"nctId":4204,"briefTitle":4205,"status":109,"phases":4206,"primaryCompletion":4207,"completion":4207,"start":576,"enrollment":771,"conditions":4208,"interventions":4210},"NCT00967252","Impact of Chronic Statin Use During Surgery on Inflammation and Infection Rates",[],"2011-07",[903,3523,4209],"Endothelial Function",[4189,4189,4189,4189],{"nctId":4212,"briefTitle":4213,"status":109,"phases":4214,"primaryCompletion":4215,"completion":4216,"start":4217,"enrollment":1066,"conditions":4218,"interventions":4221},"NCT00967434","Statin Drugs to Prevent Complications During Surgery",[93],"2010-06","2010-12","2007-12",[903,4219,4220],"Myocardial Infarction","Myocardial Ischemia",[4189,4189],{"intervention":4223,"totalTrials":164,"cells":4224},"amiodarone",{"EARLY_PHASE1":4225,"PHASE1":4227,"PHASE2":4229,"PHASE3":4231,"PHASE4":4233,"NA":4242},{"trials":4226,"activeCount":101},[],{"trials":4228,"activeCount":101},[],{"trials":4230,"activeCount":101},[],{"trials":4232,"activeCount":101},[],{"trials":4234,"activeCount":101},[4235],{"nctId":4236,"briefTitle":4237,"status":109,"phases":4238,"primaryCompletion":603,"completion":4239,"start":3076,"enrollment":2520,"conditions":4240,"interventions":4241},"NCT01461733","Atrial Fibrillation Without Hemodynamic Instability in the Intensive Care Unit",[92],"2009-12",[152],[4223],{"trials":4243,"activeCount":101},[4244],{"nctId":4245,"briefTitle":4246,"status":548,"phases":4247,"primaryCompletion":4248,"completion":4249,"start":4250,"enrollment":1257,"conditions":4251,"interventions":4252},"NCT04392921","Prophylaxis for Patients at Risk to Eliminate Post-operative Atrial Fibrillation",[93],"2024-03","2024-04","2022-03-07",[152],[4253],"Amiodarone",{"intervention":4255,"totalTrials":234,"cells":4256},"Celecoxib",{"EARLY_PHASE1":4257,"PHASE1":4259,"PHASE2":4261,"PHASE3":4263,"PHASE4":4265,"NA":4267},{"trials":4258,"activeCount":101},[],{"trials":4260,"activeCount":101},[],{"trials":4262,"activeCount":101},[],{"trials":4264,"activeCount":101},[],{"trials":4266,"activeCount":101},[],{"trials":4268,"activeCount":101},[4269],{"nctId":4270,"briefTitle":4271,"status":109,"phases":4272,"primaryCompletion":1335,"completion":1335,"start":3239,"enrollment":868,"conditions":4273,"interventions":4274},"NCT01186887","A Trial Assessing the Outcome of Celecoxib Administration Versus Placebo Following Anterior Cruciate Ligament (ACL) Reconstruction",[93],[2313],[4255],{"intervention":1177,"totalTrials":234,"cells":4276},{"EARLY_PHASE1":4277,"PHASE1":4279,"PHASE2":4281,"PHASE3":4283,"PHASE4":4285,"NA":4287},{"trials":4278,"activeCount":101},[],{"trials":4280,"activeCount":101},[],{"trials":4282,"activeCount":101},[],{"trials":4284,"activeCount":101},[],{"trials":4286,"activeCount":101},[],{"trials":4288,"activeCount":101},[4289],{"nctId":1170,"briefTitle":1171,"status":548,"phases":4290,"primaryCompletion":1173,"completion":1174,"start":1175,"enrollment":492,"conditions":4291,"interventions":4292},[93],[1177,1025,1178,1179],[1177,1025,1181],{"intervention":1181,"totalTrials":234,"cells":4294},{"EARLY_PHASE1":4295,"PHASE1":4297,"PHASE2":4299,"PHASE3":4301,"PHASE4":4303,"NA":4305},{"trials":4296,"activeCount":101},[],{"trials":4298,"activeCount":101},[],{"trials":4300,"activeCount":101},[],{"trials":4302,"activeCount":101},[],{"trials":4304,"activeCount":101},[],{"trials":4306,"activeCount":101},[4307],{"nctId":1170,"briefTitle":1171,"status":548,"phases":4308,"primaryCompletion":1173,"completion":1174,"start":1175,"enrollment":492,"conditions":4309,"interventions":4310},[93],[1177,1025,1178,1179],[1177,1025,1181],{"intervention":4312,"totalTrials":234,"cells":4313},"Combining bacteriophage therapy with antibiotics for a case with hip PJI",{"EARLY_PHASE1":4314,"PHASE1":4316,"PHASE2":4318,"PHASE3":4320,"PHASE4":4322,"NA":4324},{"trials":4315,"activeCount":101},[],{"trials":4317,"activeCount":101},[],{"trials":4319,"activeCount":101},[],{"trials":4321,"activeCount":101},[],{"trials":4323,"activeCount":101},[],{"trials":4325,"activeCount":101},[4326],{"nctId":4327,"briefTitle":4328,"status":4329,"phases":4330,"conditions":4331,"interventions":4333},"NCT06798168","Bacteriophage Clinical Trial for Periprosthetic Joint Infection of Multidrug Resistant Pseudomonas Aeruginosa","AVAILABLE",[],[4332],"Joint Infection",[4312],{"intervention":4335,"totalTrials":234,"cells":4336},"Budesonide irrigation",{"EARLY_PHASE1":4337,"PHASE1":4339,"PHASE2":4341,"PHASE3":4343,"PHASE4":4345,"NA":4347},{"trials":4338,"activeCount":101},[],{"trials":4340,"activeCount":101},[],{"trials":4342,"activeCount":101},[],{"trials":4344,"activeCount":101},[],{"trials":4346,"activeCount":101},[],{"trials":4348,"activeCount":101},[4349],{"nctId":4350,"briefTitle":4351,"status":1952,"phases":4352,"primaryCompletion":3424,"completion":3424,"start":4216,"enrollment":164,"conditions":4353,"interventions":4355},"NCT01373528","Impact of Topical Sinonasal Budesonide Irrigation on Hypothalamic-Pituitary-Adrenal Axis Function",[93],[4354],"Chronic Rhinosinusitis",[4335],{"intervention":4357,"totalTrials":234,"cells":4358},"Regular Treatment for Syphilis",{"EARLY_PHASE1":4359,"PHASE1":4361,"PHASE2":4363,"PHASE3":4365,"PHASE4":4367,"NA":4369},{"trials":4360,"activeCount":101},[],{"trials":4362,"activeCount":101},[],{"trials":4364,"activeCount":101},[],{"trials":4366,"activeCount":101},[],{"trials":4368,"activeCount":101},[],{"trials":4370,"activeCount":101},[4371],{"nctId":4372,"briefTitle":4373,"status":1952,"phases":4374,"primaryCompletion":4375,"completion":4375,"start":2040,"enrollment":2520,"conditions":4376,"interventions":4381},"NCT01540227","Penicillin Therapeutic Drug Monitoring in the Treatment of Infectious Syphilis.",[],"2016-11-10",[4377,4378,4379,4380],"Syphilis","Primary Syphilis","Secondary Syphilis","Early-Latent Syphilis",[4357],{"intervention":4383,"totalTrials":234,"cells":4384},"Transfusion",{"EARLY_PHASE1":4385,"PHASE1":4387,"PHASE2":4389,"PHASE3":4391,"PHASE4":4393,"NA":4395},{"trials":4386,"activeCount":101},[],{"trials":4388,"activeCount":101},[],{"trials":4390,"activeCount":101},[],{"trials":4392,"activeCount":101},[],{"trials":4394,"activeCount":101},[],{"trials":4396,"activeCount":101},[4397],{"nctId":4398,"briefTitle":4399,"status":109,"phases":4400,"primaryCompletion":4401,"completion":4401,"start":4402,"enrollment":4403,"conditions":4404,"interventions":4406},"NCT00326924","Age of Red Blood Cells in Premature Infants Study (ARIPI)",[93],"2012-06","2006-05",377,[4405],"Premature Birth",[4383],{"intervention":4408,"totalTrials":234,"cells":4409},"Polypharmacy",{"EARLY_PHASE1":4410,"PHASE1":4412,"PHASE2":4414,"PHASE3":4416,"PHASE4":4418,"NA":4420},{"trials":4411,"activeCount":101},[],{"trials":4413,"activeCount":101},[],{"trials":4415,"activeCount":101},[],{"trials":4417,"activeCount":101},[],{"trials":4419,"activeCount":101},[],{"trials":4421,"activeCount":101},[4422],{"nctId":4423,"briefTitle":4424,"status":109,"phases":4425,"primaryCompletion":2334,"completion":2334,"start":4426,"enrollment":4427,"conditions":4428,"interventions":4432},"NCT03133182","Polypharmacy and Outcomes After Elective Noncardiac Surgery",[],"2002-04",266499,[4408,4429,4430,4431],"Surgical Procedure, Operative","Morality","Epidemiology",[4408],{"intervention":4434,"totalTrials":234,"cells":4435},"High dose ACE-I vs ARB",{"EARLY_PHASE1":4436,"PHASE1":4438,"PHASE2":4440,"PHASE3":4442,"PHASE4":4444,"NA":4446},{"trials":4437,"activeCount":101},[],{"trials":4439,"activeCount":101},[],{"trials":4441,"activeCount":101},[],{"trials":4443,"activeCount":101},[],{"trials":4445,"activeCount":101},[],{"trials":4447,"activeCount":101},[4448],{"nctId":4449,"briefTitle":4450,"status":109,"phases":4451,"completion":2369,"start":4452,"enrollment":196,"conditions":4453,"interventions":4455},"NCT00212901","High Dose Ace Inhibitor Therapy Versus Combination of ACE and ARB Therapy",[93],"2004-08",[4454],"Diabetic Kidney Disease",[4434],{"intervention":4457,"totalTrials":234,"cells":4458},"Floseal",{"EARLY_PHASE1":4459,"PHASE1":4461,"PHASE2":4463,"PHASE3":4465,"PHASE4":4467,"NA":4469},{"trials":4460,"activeCount":101},[],{"trials":4462,"activeCount":101},[],{"trials":4464,"activeCount":101},[],{"trials":4466,"activeCount":101},[],{"trials":4468,"activeCount":101},[],{"trials":4470,"activeCount":101},[4471],{"nctId":4472,"briefTitle":4473,"status":109,"phases":4474,"primaryCompletion":4475,"completion":4475,"start":2838,"enrollment":19,"conditions":4476,"interventions":4478},"NCT01098578","Floseal Treatment for Posterior Epistaxis Study",[93],"2011-11",[4477],"Epistaxis",[4457],{"intervention":4480,"totalTrials":234,"cells":4481},"Treatment strategy using evidence-based guidelines for asthma or COPD",{"EARLY_PHASE1":4482,"PHASE1":4484,"PHASE2":4486,"PHASE3":4488,"PHASE4":4490,"NA":4492},{"trials":4483,"activeCount":101},[],{"trials":4485,"activeCount":101},[],{"trials":4487,"activeCount":101},[],{"trials":4489,"activeCount":101},[],{"trials":4491,"activeCount":101},[],{"trials":4493,"activeCount":101},[4494],{"nctId":4495,"briefTitle":4496,"status":109,"phases":4497,"primaryCompletion":4498,"completion":4498,"start":4499,"enrollment":4500,"conditions":4501,"interventions":4503},"NCT03148210","Undiagnosed COPD and Asthma Population Study (UCAP)",[93],"2024-01-09","2017-06-05",508,[4502,2678],"Asthma",[4480]]